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The Groebke-Blackburn-Bienaymé reaction  
André Boltjes[a] and Alexander Dömling*[a] 
Abstract: Imidazo[1,2a]pyridine is a well-known scaffold in 
many marketed drugs, such as Zolpidem, Minodronic acid, 
Miroprofen and DS-1 and it also serves as a broadly applied 
pharmacophore in drug discovery. The scaffold revoked a 
wave of interest when Groebke, Blackburn and Bienaymé 
reported independently a new three component reaction 
resulting in compounds with the imidazo[1,2-a]-heterocycles 
as a core structure. During the course of two decades the 
Groebke Blackburn Bienaymé (GBB-3CR) reaction has 
emerged as a very important multicomponent reaction 
(MCR), resulting in over a hundred patents and a great 
number of publications in various fields of interest. Now two 
compounds derived from GBB-3CR chemistry received 
FDA approval. To celebrate the first 20 years of GBB-
chemistry , we present an overview of the chemistry of the 
GBB-3CR, including an analysis of each of the three 
starting material classes, solvents and catalysts. 
Additionally, a list of patents and their applications and a 
more in-depth summary of the biological targets that were 
addressed, including structural biology analysis, is given. 
Introduction: Medicinal chemistry and 
Multicomponent reactions 
Design and synthesis of biological active compounds 
are an important field of chemistry as to date there are 
still many conditions, lacking treatment possibilities. 
Introduction of novel drugs continuously improve human 
health despite dramatic increase in world population. 
The continuous discovery of new biological pathways 
and the protein targets involved are a great source for 
medicinal chemist to fill the void in drugs for unmet 
medical needs. Where the work of structural biologists 
ends, in elucidating the dynamics and crystallographic 
structures of large biological structures, medicinal 
chemists start by the design of agonists and antagonist 
for those proteins and enzymes. By mimicking the 
shape and electrostatics of a small natural ligand for 
example, small molecules can be used to influence 
those natural processes resulting in inhibition or 
activation of the associated pathways. Diversity oriented 
synthesis is often applied to discover small molecules 
and to optimize their binding affinity in receptor binding 
sites.[1] Introduction of structural diversity is usually 
accomplished by the stepwise introduction of the 
individual moieties in the target molecule and each 
structural variation requires repetition of a part or even 
whole synthesis route. This divergent and sequential 
approach for the synthesis of compound libraries can be 
quite challenging and material and time consuming. A 
more convenient way would be to assemble a versatile 
scaffold and obtaining the variations in a single reaction 
step. With two component reactions the divergent 
synthesis of very large chemical space and size based 
on available building blocks is naturally limited. 
Multicomponent reactions (MCR), however, allow for the 
concomitant variation of three or more building blocks at 
the same time and consequently span a very large 
chemical space. Since the degree of the reaction enters 
the exponential, the chemical space is naturally much 
larger the higher the degree of the reaction. E.g. for 2-
component and 5-component reaction based on 1.000 
building blocks of each variable class, 1.000.000 and 
1.000.000.000.000.000 products can be expected, 
respectively. This exponential explosion of chemical 
space is key to the philosophy of MCRs.[2] MCRs allow 
for the introduction of various scaffold shapes 
introduced through several MCR variants such as Ugi 3-
component reaction (U-3CR)[3], Passerini (P-3CR)[4], 
Gewald (G-3CR)[5], Groebke-Blackburn-Bienaymé 
(GBB-3CR)[6-8], Biginelli (B-3CR)[9] and many other MCR 
name reactions. Decorating and derivatization of the 
scaffolds is simply done by choosing different starting 
materials (building blocks). For example, in the Ugi-4CR, 
with 100 different amines, aldehydes, carboxylic acids 
and isocyanides as reagents, 100 x 100 x 100 x 100 = 
108 different compounds can be synthesized, all 
connected to the dipeptidic Ugi scaffold. Such 
information rich chemical space has found recently 
applications in advanced information technology such 
as molecular steganography.[10] Clearly, the large 
chemical MCR space comprise an excellent playground 
for drug hunters. Of course there are more different 
starting materials available, and other MCR reactions, 
where bi-functional orthogonal starting materials could 
lead to even more complex (poly)cyclic structures in 
post modifications, such as UDC-procedures (Ugi-
Deprotection-Cyclization) and Passerini-reaction-Amine-
Deprotection-Acyl-Migration (PADAM) and giving 
access to a nearly unlimited number of compounds of 
most diverse shape and electrostatics and composition 
of 3D pharmacophores.[11-12] The isocyanide-based 
multicomponent reactions (IMCR), U-3CR, P-3CR, van 
Leusen (vL-3CR)[13], GBB-3CR and variations, are 
nowadays the most popular types of MCR because of 
the versatile behavior of the isocyanides, carbene-type, 
-anion and radical reactivity as well as the excellent 
atom economy. Examples of marketed drugs and lead 
compounds made by an MCR approach are Xylocaine 
(Ugi-3CR)[14], Nifedipine (Hantzsch)[15], Telaprevir 
(Passerini-3CR)[16] and Crixivan (Ugi-4CR)[17] (Scheme 
1). It is estimated that approximately 5% of the currently 
marketed drugs can be advantageously assembled by 
an MCR. Thus MCR scaffold are clearly ‘drug-like’. 
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Groningen Research Institute of Pharmacy, University of Groningen 
A. Deusinglaan 1, Groningen (The Netherlands)1 
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Scheme 1. Drug synthesized using MCR reactions. The scaffold originating from the MCR is marked in blue or purple. The central piperazine 
element of the HIV protease inhibitor Crixivan was enantioselectively synthesized by U-4CR, the local anesthetic Xylocaine can be 
advantageously synthesized in one step using U-3CR, the cardiovascular blockbuster drug Nifedipin by a Hantzsch-3CR and the stereochemical 
complex HCV protease inhibitor Telaprevir by a combination of P-3CR (purple) and U-3CR (blue) thus reducing the total number of steps by half. 
 
Here we will focus on one of the youngest IMCRs, the 
GBB-3CR based on its enormous interest in applied 
chemistry. The development of the reaction started by 
Groebke et al. (Hoffman-La Roche), initially published 
as a side reaction of the U-4CR. While studying the 
effect of various amine components, it was found that 
amines with a cyclic H2N-C=N substructure (2-
aminoazines or amidines), such as 2-aminopyridine, 2-
aminopyrazine and 2-aminopyrimidine were yielding the 
corresponding 3-amino-substituted imidazo[1,2-a]-
pyridines, -pyrazines and -pyrimidines respectively.[6] In 
this report, they made the reference to Sugiura et al. 
and suggests that the very first report of the GBB-3CR 
methodology was made almost 30 years earlier by 
condensing 2-aminopyrazine with formaldehyde, the 
nitrile compound and sodium or potassium cyanide. This 
was in contrast to the conventional method to access 
imidazo[1,2a] annulated pyridines, pyrazines or 
pyrimidines whereby a heterocyclization reaction 
between α-haloketones with the corresponding amidines 
was performed.[18-19]  
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Scheme 2. The discovery of the GBB-3CR: A, General description of the GBB-3CR using amidines, aldehydes and isocyanides. B, One of the 
examples of Bienaymé using 2-aminopyrimidine, benzaldehyde, t-butylisocyanide and perchloric acid as catalyst, the formation was verified by X-
ray structure refinement (CCDC-101255). C, Blackburn et al. reporting scandium triflate as optional catalyst. D, One of the Groebke examples; 
with 2-aminopyrazine, catalyzed with acetic acid.  
 
At the very same time Blackburn et al. from Millennium 
Pharmaceuticals (USA) published their work. The 
additional value of this work is the use of scandium 
triflate as Lewis acid catalyst.[20] It follows the finding of 
Groebke et al. that the presence of an Brønsted acid, 
such as acetic acid is resulting in higher yields. This pH 
dependency results from the requirement of proton-
assisted activation of the Schiff base to enable attack of 
the isocyanide component. As a third inventor of the 
GBB-3CR, Bienaymé et al. (Rhône-Poulenc 
Technologies (France)) reported in search of new MCR 
chemistry an approach to apply two covalent bonded or 
bridged reagents and found a 3-component reaction of 
2-aminopyridine or –pyrimidine with aldehydes and 
isocyanides in the presence of a catalytic amount of 
perchloric acid in methanol. This approach was applied 
to produce 31 examples with variation points in all three 
components with yields between 33 and 98%.[8] Due to 
the nearly simultaneous reports on the discovery of this 
three component reaction the reaction was called later-
on the Groebke-Blackburn-Bienaymé 3-component 
reaction or in short the GBB-3CR. Interestingly, since its 
initial description, it took ~8 years until an exponential 
increase in reports was observed using the GBB-3CR 
methodology broadly in chemistry and also leading to 
multiple patents (Figure 1). 
 
 
Figure 1. Development of the GBB-3CR over the last two decades as indicated by increasing number of publications and patents. The numbers 
were collected through a SciFinder search (April 2019) using GBB-3CR related keywords and structure search of 5- or 6 membered GBB-3CR 
products including all variations of hetero atoms of the amidine component, corrected for the non GBB-3CR originated 3-amino-substituted 
imidazo[1,2-a]-pyridines, -pyrazines and –pyrimidines.
Quite impressively, so far, more than 200 publications 
and >100 patent applications have been reported, 
exploiting the GBB-3CR, with a clear trend of further 
increasing interest. With this in mind a few reviews were 
published, dedicated to the GBB-3CR as an MCR 
approach to access 3-amino-substituted imidazo[1,2-a]-
heterocycles. Singh et al. were the first to cover the 
reaction and addressed the used catalysts and the 
general chemistry behind the GBB-3CR.[21] 
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review, highlighting biological targets the GBB scaffold 
could be used for, possible post-modifications and to a 
certain extend the scope and limitations were discussed 
with some examples of amidines, isocyanides, 
aldehydes used in the GBB-3CR.[22] In addition Liu 
published an overview on the Asinger[23] and GBB-3CR, 
in a historical fashion with emphasis on the possible 
post modifications and applications of both reactions. [24] 
Also Liu dedicated a mini review solely on potent 
applications of the imidazo[1,2-a]-heterocycles.[25] To 
our knowledge patents were never discussed and our 
review tries to give a complementary twist by giving 
insight into all the used reactants, all the catalysts and 
solvents used in the GBB-3CR, detailed discussion of 
the structural biology, in order to get more insight in how 
GBB scaffolds interact with therapeutically relevant 
targets. 
Mechanism 
Examples of isocyanide based MCR’s (IMCR’s) are the 
P-3CR, vL-3CR, U-4CR, Ugi-azide-4CR, U-3CR, and 
GBB-3CR (Scheme 3). Aside from the P-3CR and the 
vL-3CR, the latter 3 IMCR’s are mechanistically 
variations on the U-4CR. The acid component is 
decisive in how the iminium species will react towards 
other components, rearrange and ultimately is 




Scheme 3. Overview of the most common IMCR’s. 
For example, the U-3CR is only taking the proton of 
specific acidic reagents (e.g. p-toluene sulfinic acid 
(pTSIA)) and eliminating the Mumm rearrangement that 
otherwise concludes the U-4CR. The Ugi azide-4CR 
reaction adheres to a similar mechanism as the U-3CR, 
hydrazoic acid is introduced by using sodium azide or 
TMSN3. In the GBB-3CR the additional reactivity of the 
endocyclic nitrogen in the amidine component allows for 
the formation of a different scaffold, whereas the acid 
component is not incorporated in the final product and 
serves only catalytic purposes instead. In the GBB-3CR, 
the imine intermediate is activated by a Lewis or 
Brønsted acid, and follows a formal [4+1] cycloaddition 
sequence concluding with aromatization via a 1,3-H shift 
(Scheme 4 Pathway A) to form the imidazo[1,2-
a]pyrimidine when 2-aminopyridine is used. The GBB-
3CR could follow two possible pathways leading to 
regioisomers as indicated in scheme 4. Pathway A is 






the most common and is referred to as the GBB-3CR 
and pathway B as the ‘inverse’ GBB-3CR. 
 
 
Scheme 4. Variations of the Ugi reaction and the Groebke Bienaymé Blackburn reaction. In the GBB mechanism one of the most commonly used 
amidines; 2-aminopyridine as R2-group was used in the mechanistic overview to simplify the scheme. 
2-Aminopyrimidines tend to form both regioisomers as it 
was first described by Bradley et al., trying to explain the 
low yields of some of their reactions while the starting 
materials were fully consumed.[26] Isolation of a second 
product having nearly identical TLC-Rf values, mass and 
1H NMR spectra gave reason to perform an X-ray 
structure analysis, uncovering the two regioisomers 1 
and 2 depicted in scheme 5. Luckily, the normal GBB 
product is the major product for most cyclic amidine 
building blocks, thus rendering it a quite useful synthetic 
reaction. In fact, in most cases not even traces of 
inverse GBB products can be observed. 
 
Scheme 5. Two possible regioisomers of the GBB-3CR. Left 1 (CCDC-189548) a typical GBB-3CR imidazo[1,2
-a]pyrimidine and on the right 2 (CCDC-189549) its inverse GBB regioisomer. 
Proceedings in the development of the 
GGB-3CR. 
Based on the pharmacological relevance of imidazo[1,2-
a]heterocyclic compounds and their easy access 
through the GBB-3CR, many scientists explored the 
scope and limitations of this reaction, trying a large 






variety of catalysts, solvents and temperature conditions, 
resulting in a wide variety of publications with a 
confusing high number of different conditions. Herein, 
some of the more relevant reports are discussed, 
showing important developments, noteworthy 
applications and several reaction conditions used are 
described to fully comprehend the versatile character of 
the GBB-3CR. For example, Varma et al. showed that a 
microwave (MW) assisted solvent-free method could be 
applied by the aid of montmorillonite K-10 clay.[19] The 
conditions were quite unusual that time since microwave 
assisted procedures were not yet broadly applied in 
1999. Here a household microwave was used with an 
unsealed test tube irradiated at 900 W for 3 minutes. 
Together with the clay catalyst and variations of simple 
aromatic aldehydes, various isocyanides and 2-amino-
pyridine (3), pyrazine (4) or pyrimidine (5) yields of 
>80% were obtained (Scheme 6). 
 
 
Scheme 6. Montmorillonite K-10 clay-catalyzed and solvent free GBB-3CR. 
 
Whittaker et al. showed a very similar scandium triflate 
catalyzed reaction via a microwave assisted GBB-3CR 
in 10 minutes with yields between 33-93% and using 
substituted benzaldehydes and mostly aminopyridines, 
interestingly also a 5-membered aminothiazole 
substrate was introduced, giving lower yields mostly 
related to side products (6) formed by the addition of 
methanol to the intermediate Schiff base (Scheme 7). [8, 
27] The side product formation could, however be 
suppressed by the use trifluoroethanol as a less 




Scheme 7. Application of electron-poor cyclic amidines in the GBB-3CR results in poor conversion and side reactions such as addition of MeOH 
to the Schiff base intermediate. 
 
Hulme et al. showed TMSCN as an equivalent to the 
simplest isocyanide HNC, to directly access 3-
aminoimidazo[1,2-a]pyridines 7-8, which otherwise 
would require an additional deprotection step when a 
convertible isocyanide such as the Walborski’s reagent 
(1,1,3,3-tetramethylbutylisonitrile) is used in the GBB-
3CR (Scheme 8).[28] 
 








Scheme 8. Access to N-exocyclic unsubstituted GBB products. A: Reagents and conditions: a) aminopyridine (1 equiv), R2CHO (1 equiv), 2 (1 
equiv) or benzylisonitrile (1 equiv), Sc(OTf)3 (5 mol %), 16 h; b) Aminopyridine (1.2equiv), R2CHO (1 equiv), TMSCN (1 equiv), Sc(OTf)3 (5 mol %), 
MeOH, microwave, 10 min, 140 °C. Followed by Si-trisamine (5 equiv); c) H2, EtOAc, 24 h; d) 10% TFA/CH2Cl2, 18 h B: Representative examples 
and their yields and the observed Schiff base as side product. 
 
Some side product was found to be the Schiff base 9, 
formation could be prevented by using an excess of 
amidine. After the reaction the residual catalyst Sc(OTf)3 
was removed using 5 equivalents of Si-trisamine, which 
is a powerful scavenger of electrophiles as well as an 
effective scavenger for transition metals.  
GBB-3CR products are often observed as being 
strongly fluorescent. Balakirevet al. introduced “Flugis”; 
fluorescent Ugi products as drug-like probes for the 
identification and visualization of potential targets. [29] 
The compounds described as U-3CR compounds arise 
from the GBB-3CR and were used with the rationale to 
incorporate drug-like scaffolds into fluorescent 
molecules. The often fluorescent nature of GBB 
products should be kept in mind during biophysical 
receptor-ligand screens based on fluorescence 
principles! For example, in a recent screen for inhibitors 
of the NS3/4A serine protease of the hepatitis C virus, 
some of the compounds with the [1,2-a]pyridine scaffold 
were found to exhibit auto-fluorescence in UV that 
interfered in the enzymatic fluorescence detection 
assay.[29] This led to their approach to incorporate this 
scaffold that is synthesized using the GBB-3CR in their 
search of fluorophores in a 1600 compound containing 
microarray, resulting in fluorescent imidazo[1,2a]pyridine 
compounds, which are known to interact with the 
peripheral benzodiazepine receptor (known as the 
translocator protein TPSO) and GABAA benzodiazepine 
receptors. The compounds were tested for their affinity 
with, and use as TPSO imaging probes.  
The introduction of a 18F-label to PET radiotracers 
via 18F-labelled prosthetic groups using MCR chemistry 
was discussed by Gouverneur et al.[30] Labeling of 18F 
requires reaction conditions which might not always be 
compatible with the substrate. By using 18F-
benzaldehydes in MCR assisted radiochemistry, mild 
conditions could easily be performed in the U-4CR, P-
3CR, B-3CR and GBB-3CR while maintaining a swift 
reaction necessary for the rather short half-life time of 
110 min for 18F. 
 







Scheme 9. 18F introduction in GBB-3CR products.  
The ’hot’ GBB-3CR was performed in 3-methyl-1-
butanol under conventional heating in most cases and 
some under MW conditions, where 150-170 °C was 
found to give the highest yields; 64-85% 
The use of hydrazines in the GBB-3CR has not 
been explored until 2014. A variation in which 2-
hydrazinopyridine is used to obtain bicyclic 
pyridotriazines was introduced by Hulme et al.[31] The 
proposed mechanism is quite similar to that of the GBB-
3CR reaction, it involves a non-concerted [5+1]-
cycloaddition of the Schiff base and isocyanide.  
Comparable to the example of ketones (Kumar et al. 
example in chapter 3.2) in the GBB-3CR discussed 
below, there is no rearomatization seen with both 
aldehydes and ketones, which otherwise concludes the 
GBB-3CR. The appendant moiety originating from the 
isocyanide component remains in the product as a 
stable imine (10). The reactive nature of the Schiff base 
intermediate 11 allows introduction of not only 
isocyanide, but isocyanates, acyl chlorides and cyclic 
anhydrides as well (Scheme 10). 
 
Scheme 10. A: Hydrazines undergo a GBB-like [5+1] cycloaddition to furnish bicyclic triazines. This given example was obtained in 85% yield, 
aromatic aldehydes are will not result in product formation B: The reactivity of the hydrazine derived Schiff base could be exploited for other 
transformations with various electrophiles.
 
Hulme et al. reported the use of acyl cyanide (14) as 
isocyanide replacement in the GBB-3CR. The resulting 
primary amine (15) subjected to the excess of aldehyde 
(4 eq.) and acyl cyanide (3 eq.) undergoes a 
domino/tandem acyl-Strecker reaction.[32] A great 
example of a modified GBB-3CR: on one hand the 
acetyl cyanide serves as a less toxic replacement for 
TMSCN, on the other hand a great catalyst, acetic acid 
is freed during the course of this one-pot 3-step cascade 
reaction (Scheme 11). 
 







Scheme 11. Acetyl cyanide assisted one-pot three-step GBB-Strecker cascade. 
 
In situ generation of amidines for use in the GBB-3CR 
was demonstrated by Mahdavi et al., using 2-
bromopyridine 16, sodium azide, and aldehyde and 
isocyanide in a copper-catalyzed 4CR.[33] The activated 
bromine is converted to amine 17 via a reductive 
amination as depicted in scheme 12, prior to take part in 
the GBB-3CR. The reaction sequence is described a 
one pot four component reaction, the reaction could as 
well be considered as a three-component reaction with 
in situ generated 2-aminopyridine. 
 
  
Scheme 12. The scope of the GBB-3CR was expanded by the use of 2-bromopyridine, in situ converted into the essential amidine. 
 
Procedures in process chemistry are necessarily studied 
in depth for optimal conversion to the desired products. 
In this respect the report of Mathes et al. is very useful, 
as it investigates the driving forces of the GBB-3CR, 
introducing alternative purification methods that 
circumvent labor-intensive chromatography.[34] Apart 
from the usual reagents, the Schiff base pre-formation 
was promoted by adding a catalytic amount of p-TSA. 
The following cycloaddition was in turn catalyzed by 
borontrifluoride-acetonitrile complex (BF3·MeCN) and 
two equivalents of trimethyl orthoformate as dehydrating 
agent was added to increase the rate of the reaction 
significantly, giving good yields in less than a day of 
reaction time (Scheme 13). Purification was done by 
adding 1,3 equivalents of sulfuric acid to precipitate the 
GBB-3CR products from i-PrOH as sulfate salts in high 
purity. From the optimized method, a large scale 
reaction was performed at 100 mmol scale, yielding the 
GBB product 18 in 82% yield, against 85% on 1 mmol 
scale, proving the scalability of the reaction.  
 
 
Scheme 13. The optimized one-pot two-step process of a BF3·MeCN catalyzed GBB-3CR. 
 
Using bis- (19-20) or tris amidines in the GBB-3CR 
allows for multiple MCRs in a single transformation as 
demonstrated by Lavilla et al.[35] The position of each 
amidine when applying asymmetric bis-amidine 19 
determines the reactivity and therefore the selectivity of 
the first GBB-3CR and enables introduction of different 
aldehyde and isocyanide components in the second 
GBB-3CR. This regioselectivity is also seen in 
symmetric bis-amidines, but require stoichiometric 
amounts of the aldehyde and isocyanide components. 
Reactions with the tris-amidine melamine 21 exclusively 
yielded symmetric products. The fluorescence abilities 
of the synthesized compounds was highlighted and 
through introduction of EWG or EDG functionality at 
specific locations, the fluorescence emission 
wavelengths could be tuned. Additionally BODIPY (93) 
like fluorophores were made by reacting α-pyridyl GBB-
3CR compounds with BF3OEt2, to create a BF2 bridge 
between the pyridine and imidazo rings. This bridged 
compound (23) showed a shift in the emission 
wavelength by 60 nm, a 40-fold emission increase and 










Scheme 14. Bis-amidines in the GBB-3CR: A. The Bis- and Tris amidines reacted in the GBB-3CR. B. Asymmetric product formation using 
different aldehydes and isocyanides in two separate MCRs. C. Enhancement of fluorescent properties by introduction of a BF2 bridge. 
Scope and limitations of the GBB-3CR. 
Immediately after the introduction of the GBB-3CR 
approach to access imidazo[1,2-a] heterocycles, the 
scope and limitations were elaborated. However, in 
each of the attempts only a small selection of variables 
was assessed. This went from solvent screening, 
varying reaction conditions, catalysts and reagent use to 
solid phase approaches. A good example is the use of 
glyoxylic acid to obtain an uncatalyzed formaldehyde-
based product. In the general scope and limitation of the 
GBB-3CR it was found that the reaction is best 
performed at room temperature in MeOH, with a 
concentration ranging between 0.3-1.0 M, using 
arylaldehydes, 2-aminopyridines, and aliphatic 
isocyanides in stoichiometric amounts, in the presence 
of a catalytic amount of 10 mol-% Sc(OTf)3. Difficulties 
in predicting reactivity were found with some 
combinations of starting materials and cannot always be 
attributed to electronic factors, as steric effects have a 
significant effect as well, illustrated in figure 2. [35] 
 
 
Figure 2. Steric effects in the GBB-3CR. The bulk effect of t-butyl prevents the reaction from happening, the optimized geometry was calculated 
for compound 24, exchanging the t-But- for a cyclohexyl moiety, affording compound 25 in a good yield.
 Aliphatic aldehydes give good yields when aromatic 
isocyanides are used, however, when both aldehyde and 






isocyanide are both electron rich, a reduction in yield was 
described recently.[34] Although such findings are valuable 
starting point for better understanding the GBB-3CR, we’ve 
tried to illustrate the scope and limitations in a broader 
sense, including the effect of substituents on each of the 
reported starting materials. Therefore, a tabular summary of 
amidines, aldehydes, isocyanides and catalysts used in the 
GBB-3CR is presented in the following. Additionally, the 
tables act as reference guide to which components are 
suitable, including every report the component was 
successfully used in. The benefit here is a complete and 
simple access to the possible starting materials, grouped 
according to aromatic, hetero aromatic and aliphatic nature 
and electron donating or withdrawing substituents (EDG 
and EWG respectively) and bulkiness. Thus a quick look in 
the tables can reveal unambiguously which component has 
been used previously and will likely work in other instances. 
Cyclic Amidines in the GBB-3CR 
The amidines are key to give the scaffold its typical 
imidazo[1,2-a] heterocyclic form, whereas the aldehyde 
and isocyanide components are more appendant 
substituents, sometimes called scaffold decoration. 
Nearly 90 different amidines were used in GBB-3CR, of 
which 22 are five membered and 66 are six membered 
amidines. All of them were sorted in table 1 according to 
ring size, type and additional substituents. The most 
abundant amidine in the table, 2-aminopyridine is where 
the GBB-3CR was discovered with and is not 
surprisingly used in many model reactions to test other 
solvents and catalysts. Substituted 2-aminopyridines 
also show good reactivity, giving products in good yields. 
Electron withdrawing substituents, mostly halogens 
seem to increase the yield, with the exception of nitro-
groups. Alkyl groups and other more EDG generally 
give lower yields. More electron deficient pyrimidines 
give lower yields in the GBB-3CR, both 2- and 4-
aminopyrimidine with EWG substituents were reported 
as low yielding. Aminopyrazines are overall reported as 
good yielding. A broad range of 5-membered amidines 
appears often with other hetero atoms, such as 
oxazoles and thiazoles, and are not very reactive 
resulting in less good yields. 3-Amino-1,2,4-triazole, on 
the other hand, is reported as good yielding amidine. 
Nucleobase derived compounds are popular as they 
possess good hydrophilicity and solubility, which are 
therefore potentially therapeutically relevant 
heterocycles. Adenine 26, guanine 27 and cytosine 28 
are nucleobases that bear an amidine moiety which was 
exploited in the GBB-3CR by Madaan et al. to furnish 
aminoimidazole-fused nucleobases.[36] The polar nature 
of these amidines required a more polar solvent than 
methanol, as this solvent did not yield any product at all. 
The screened solvents PEG-400, ethylene glycol, 
DMSO, DMA and DMF all give product, with yields 
varying between 23 to 68% with ZrCl4 in DMSO as a 
catalyst (Scheme 15). Even the otherwise difficult to 
modify guanine is giving GBB-3CR products albeit in 
rather low yields. 
 
 
Scheme 15. Synthesis of aminoimidazole-condensed nucleobases.
  
Table 1. Amidines applied in the GBB-3CR. Those with R groups have multiple similar substitutions, used for producing derivatives. *This amidine 
has 10 more examples of N substituted piperazines [37-38] 
 







[8, 19, 30, 33, 38-122] 
 
[28, 34, 57, 64, 68, 
71, 79, 81, 87, 91, 




[27-28, 41-42, 46, 
51-52, 54-57, 60, 
64-65, 68-69, 71, 






[41, 57, 63-64, 74-
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[64, 75, 98, 118, 
120-121, 132-133] 
 
[27, 51-52, 54-57, 
59-60, 63-66, 68, 70, 
73-76, 85, 94, 97, 
100, 102, 105, 108-

















[8, 30, 41, 52, 59, 
63-64, 66, 68, 75, 
86, 95, 102-103, 
108-110, 112-113, 
116, 119, 121-123, 
125, 128, 130, 135] 
 
















[64] [102]  
[86] 
 
[29]  [8, 40, 42, 52, 75, 




[8, 65, 96] 
 







[29, 75, 86, 89, 102-
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[8, 19, 26-27, 29, 
38-41, 43, 47, 49, 
58, 61, 63, 66, 73-
74, 86, 97, 102-



















[147]  [148] 
 
[8, 19, 29, 34, 38-
40, 42-43, 48, 53-
54, 56, 58-59, 61, 
63, 66, 68, 72-75, 
80, 86, 88-89, 94, 
96-97, 101-103, 
105, 108, 110, 
112, 114, 123, 































[63, 114] [162-163] 
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[58, 80, 105, 110, 






[8, 27, 29, 46, 59, 




















A feature which can be generally observed with many 
MCRs is their great functional group compatibility. Thus, 
heteroaromatic amidines can comprise all halogens, 
and pseudo halogens such as nitrile, nitro, methoxy, 
free carboxylic acids, esters, unprotected primary and 
secondary amines, unprotected phenolic and aliphatic 
hydroxyl, amides, alkynes, alkenes, and boronic acid 
esters. This great functional group compatibility is 
important for further reactivity of the initial GBB-3CR 
products and also for optimal interaction within a 
receptor pocket.  
Aldehydes 
Aldehydes are common building blocks which are cheap 
and have good commercial availability and with 180 
different records they are very broadly applicable in the 
GBB-3CR reaction with great variability (Table 2). The 
diversity of aldehydes found is broad, from aromatic to 
aliphatic aldehydes with many different substituents, 
both electron withdrawing and donating and bulky and 
small groups and also aldehydes containing reactive to 
labile protective groups that allow secondary 
modifications. Aromatic aldehydes generally form stable 
Schiff bases, where an effective conjugation system is 
beneficial for its stability. Schiff bases from aliphatic 
aldehydes are found to be less stable and readily 
polymerize, which translates to reduced yields of 
subsequent transformations. Benzaldehyde is the 
mostly used aldehyde for reasons such as detectability 
on TLC for reaction monitoring and good reactivity. 
Substituents on benzaldehydes do affect their reactivity. 
Using substituted benzaldehydes bearing an electron 
donating group usually increases the yields, whereas 
withdrawing substituents reduce the yields. 
It would be an extensive exercise to discuss every 
variant in detail, therefore the more interesting examples 
were highlighted. The use of formaldehyde in order to 
obtain 2-unsubstituted-3-amino-imidazoheterocycles in 
the GBB-3CR was not reported until 2004 by Kercher et 
al.[42] Successful preparations of the unsubstituted 
imidazole were actually scarce and the few reports that 
did, showed low yields in non-efficient synthetic 
routes.[173-175] In this report formaldehyde (aqueous) and 
paraformaldehyde were used, resulting in poor yields of 
36 and 44% respectively. Other formaldehyde 
substitutes were screened, showing that glyoxylic acid is 
giving good yields up to 71% with glyoxylic acid 
immobilized on macroporous polystyrene carbonate 
(MP-CO3) 29 in an uncatalyzed GBB-3CR reaction 
(Scheme 16).  
 
 
Scheme 16. Formaldehyde and formaldehyde surrogates in the GBB-3CR and their associated yields. 
 
Kenedy et al. reported three examples with the 
successful use of paraformaldehyde with varying yields 






between 68-78% in a microwave assisted GBB-3CR in 
MeOH, catalyzed with 4 mol-% MgCl2 at 160 °C in just 
10 minutes.[136]  
The first ketone example in a tetracyclic fused 
imidazo[1,2-a]pyridines from isatin 30 was reported by 
Che et al.[119] The special multi-reactive nature of isatin 
is allowing for a formal [4+1] cycloaddition with different 
isocyanides and subsequent rearomatization via [1,5]-H 




Scheme 17. Two possible reaction pathways with the -ketoamide isatin and some examples of the GBB-3CR ran with other ketones. 
Using other ketones, Kumar et al. reports the synthesis 
of spiro-heterocycles catalyzed with TiO2 nanoparticles 
in excellent yields.[170] The quaternary spiro carbon lacks, 
however, the proton required for [1,3]-H shift, therefore 
rearomatization of the unstable [4+1] adduct could not 
take place. These adducts were reported as the 
products and also contains an example of an isatin 
containing product 32, wherein the structure was found 
to be surprisingly different from the isatin products 
described by Che et al.[119] The conflicting structures are 
not likely to be attributed to the amidine and isocyanide 
components and the right structure is without 
appropriate structure elucidation such as X-ray 
diffraction spectroscopy difficult to confirm.  
The aldehyde pyridoxal 76 has a different outcome 
and will not result in the typical GBB-3CR scaffold when 
reacted with an amidine and isocyanide. The resulting 
product formed instead, a furo[2,3c]pyridine 78, was 
shown in scheme 32 and further discussed in the 
biologically active compounds section. 
 
 
Table 2. The large variety of aldehydes sorted by origin and substituents. 
 
[8, 19, 26, 28, 33-34, 37-40, 43, 46-47, 50-
51, 53-55, 58, 60, 63, 70-73, 76, 79-80, 83-
85, 89-90, 92-93, 96, 100, 104-107, 109, 
111, 114, 117, 124, 126-127, 131-133, 136, 
140, 143, 145, 148-150, 152, 155-156, 158, 




[6, 26, 28, 40, 73, 
83, 107] 
[6, 19] [29, 165] 
 
[27, 114, 162] 
 






37, 43, 46, 51, 54-
55, 60, 76, 90, 100, 
105, 109, 114, 124, 
126-127, 132-133, 






[166]  [92-93, 141] 



















[59, 63, 70, 83, 




[72-73, 133, 152] 
 
[92-93, 133, 144, 148, 
158, 167, 177] 
 
[6, 19, 29, 33-34, 36, 
39, 43, 50, 54-55, 
59, 63, 68, 74, 77, 
83, 90, 94, 100, 105-
107, 114, 117, 126, 
131-133, 136, 140, 
143, 145-148, 150, 
152-153, 155, 157-
158, 166-167, 172] 
 
[29, 43, 63, 106, 
158] 
 
[29, 65, 69, 78, 
89, 153, 158] 
 
[50, 117, 141, 








[8, 36, 59, 69, 74, 










[43, 117, 166] 
 

























[134, 144, 158] 
 






















[68, 72, 83, 92, 104-
105] 
 
[29, 68, 104, 117, 
140, 142, 144, 
155, 158, 169] 
 
















[95, 118]  
[106] 







[59, 123, 163] 
 
[52, 87, 106, 125, 159]  [20, 26, 38-39] 
 
[58, 62-63, 80] 
 




















[47, 64, 67, 85, 
135, 148, 167, 
172] 
 
[29, 33-34, 36, 43, 46-
47, 51, 54, 59-60, 63, 
68-71, 74, 76-77, 79, 
82-83, 85, 88, 90, 94, 
100, 106, 111, 124, 
132, 143, 146-147, 
150, 152, 158, 167-
168, 172, 176] 
 


























148, 150, 169] 
 
[30, 34, 37-38, 43, 47, 
68, 85, 88-89, 94, 96, 
105, 114, 141, 144-
145, 147, 150, 158, 
164-165, 168, 172] 
 




























[74, 105, 130, 
133] 
 
[29, 33, 36, 59, 
69, 85, 90, 94, 
109, 114, 117, 






[8, 27, 47, 63, 
100, 105, 121, 
131, 133, 164] 
 
[8, 28-29, 50, 81, 88, 
96, 133, 136, 145, 149, 
158] 
 
[51, 55, 68, 72, 106, 
124, 126, 147, 158] 
 
[8, 105, 139-140, 
158, 162] 
 
[29, 33, 68-69, 71, 
79, 83, 85, 88, 92-
93, 111, 114, 140-
141, 145-148, 
152-153, 158, 
162, 164, 167, 
172] 
 
[51, 54-55, 60, 
71, 79, 85, 88, 
100, 111, 114, 
124, 126-127, 













[128]  [86] 
 



































[50, 92-93, 106, 114, 












[8, 28-29, 58, 81, 85, 
90, 92-93, 105, 127, 
133, 141, 144, 158] 
 
[135, 143]  [135] 
 






























[38, 44, 47, 50, 59, 83, 
92, 141, 176] 
 
[8, 84, 107, 136, 
165] 
 
[28, 40, 47, 107] 
 
[83, 96, 105, 133] 
 
[19-20, 36, 47, 
100] 
 





































     
  






[170] [170] [170] [119] [170] 
Interestingly, 2-siloxycyclopropanecarboxylates were 
applied as aldehyde substitutes to obtain GBB-3CR 
compounds with a δ-amino acid backbone.[45] The 
siloxanes go through a ring opening pathway and 
behave as the aldehyde component 33, together with 2-
aminopyridine and p-methoxyphenyl isocyanide 34, 
catalyzed with acetic acid in MeOH to give methyl (3-
aminoimidazo[1,2-a]pyridin-2-yl)propanoates in 
moderate to good yields (Scheme 18). 
 
 
Scheme 18. 2-Siloxycyclopropanecarboxylates as aldehyde substitutes in the GBB-3CR. One example of a GBB product 35 synthesized from 2-
siloxypropanecarboxylates and its resolved X-ray structure (CCDC-601760), in total 8 products were synthesized with variations on the amines, 
isocyanides with yield varying 40-79%. 
Again the functional group compatibility of the GBB-3CR 
aldehyde component is amazing and comprises 
aromatic benzaldehydes include substitutions on all 
positions with alkyl, aryls, alkoxy groups, alcohols, acids, 
nitro groups, cyano groups, tertiary amines, 
polyaromatics and fused heterocycles. Aliphatic 
aldehydes are also widely represented, including 
saturated and unsaturated alkyl groups (1°, 2° and 3°), 
substituted with alcohols, esters, adjacent carbonyls, 
thiols and cyclic alkyl groups. Thus, heteroaromatic 
amidines can comprise all halogens, and pseudo 
halogens such as nitrile, nitro, methoxy, free carboxylic 
acids, esters, unprotected primary and secondary 
amines, unprotected phenolic and aliphatic hydroxyl, 
amides, alkynes, alkenes, and boronic acid esters. This 
great functional group compatibility is important for 
further reactivity of the initial GBB-3CR products and 
also for optimal interaction within a receptor pocket.  
Isocyanides used in the GBB-3CR 
The commercial availability of isocyanides is limited and 
those available are often expensive, likely because of 
the stability, applicability and the undesirable smell of 
most liquid isocyanides. Therefore only a few dozen of 
isocyanides are commonly used in many isocyanide-
based MCRs. Due to the pricing and availability 
isocyanides are often prepared in house. Preparation of 
isocyanide from primary amines via the Hoffman- or Ugi 
route (formylation & dehydration) is most common and 
recently the substrate scope has been broadened by 
conversion of cheap and broadly available oxo-
compounds (aldehydes and ketone) to isocyanides by 
the repurposed Leuckart-Wallach reaction as described 
by Dömling et al.[178] Altogether an astonishing 100 
different isocyanides were reported in the GBB-3CR, 
proving that the isocyanide variation point is broadly 
exploited and is hardly to be considered as a limitation 
of variability in this three component reaction. Aromatic 
and aliphatic isocyanides participate with equal ease in 
the GBB-3CR, although it must be noted that 
combinations of bulk substituents affect the yield when 
bulky amidines and aldehydes are used simultaneously. 
Not surprisingly, there is again a great functional group 
compatibility. This includes aliphatic isocyanides widely 
substituted, heterocycles, substituted with esters, 
alcohols and ethers. Also a broad selection of 
substituted phenyl isocyanides are compatible, with 
substitutions on all positions with alkyls, halogens, 














Table 3. Nearly 100 reported isocyanides used in the GBB-3CR and sorted by type and substituents. 
 
[8, 19, 26, 29, 33, 36-38, 45-46, 49-51, 54-
60, 62-63, 66, 69, 71-74, 76, 79-81, 85-86, 
89, 91-93, 95, 97-98, 100-105, 109-116, 118-
120, 122, 124, 126-127, 135-136, 139-140, 
144, 146-147, 152-157, 159-162, 164-165, 
167, 169, 171-172, 176] 
 
[8, 19, 26, 28, 36, 
42, 45-47, 53, 56, 
63, 73, 76, 95, 97, 
100, 102, 104-105, 
110, 117, 127, 136, 
143, 156, 160-161, 
164-165] 
 
[29, 34, 52, 61, 





[41, 52, 61, 66, 
73-74, 125, 134, 
156, 170] 
 
[73, 128, 134, 152, 
159, 162-163] 
 




[37, 66, 128, 134, 
140, 145] 
 
[8, 19, 29-30, 33-34, 36, 41, 46, 49-52, 
54-57, 60-61, 64-65, 67, 69-74, 76, 79-
81, 85-86, 90-93, 95, 97-98, 100, 105-
106, 111-112, 114, 117-121, 124, 126-
128, 131, 136, 139-140, 144, 146-148, 







[73, 117, 121] 
 










[73, 102, 159] 
 
[29, 50, 69, 74, 
78, 89, 114, 159] 
 
[8, 48, 77]  
[8] 
 
[42, 48, 52, 58, 
78, 87, 89, 105, 
108, 115-116, 
122, 132, 165] 
 


























[87]  [48] 
 
[43, 47, 77, 92, 









[8, 42, 48, 50, 55, 












[34, 36, 42, 45, 
66, 72-73, 75, 86, 
101, 118, 120, 
130-131, 141-142, 

















[29, 43, 77, 134, 











































[19-20, 27-29, 41-42, 
45, 47-49, 52, 58, 65-
66, 70, 72-73, 77, 80, 
86, 89, 97-98, 100, 
112, 118, 120-121, 
125, 129-130, 132, 
136, 140, 153, 156, 
159, 162-163, 171] 
 









[98, 129, 132, 

























      
Catalysts in the GBB-3CR 
From the moment the GBB-3CR was discovered, Lewis 
and Brønsted acid catalyst were used for an efficient 
transformation. Saying this, it is possible to run the 
GBB-3CR without the aid of a catalyst, it generally 
depends on the nature of the reagents. Low electrophilic 
aldehydes such as various benzaldehydes are 
suspected to be unable to condensate with electron 
deficient amidines, whereas the addition of Lewis acids 
would increase the reactivity of the imine formation 
considerably.[145] In figure 3 the occurrence of the 
catalysts used in the GBB-3CR are mapped. Clearly 
scandium triflate has the highest success rate followed 
by the Brønsted acids HClO4, p-TSA and acetic acid. 
However, when taking into account that early adaptors 






of the GBB-3CR were basically reproducing reaction 
conditions, the frequency of some of the applied 
catalysts is artificially higher and are possibly not the 
best catalysts in the given reactions. Examples of such 
catalysts are acetic acid and Montmorillonite k-10 clay 
which appear mostly in the first few years after the 
discovery of the GBB-3CR. Additionally some catalysts 
were reported multiple times, however from the same 
research groups, introducing a biased success rate.  
  
Figure 3. Overview of GBB catalysts that performed best in reported catalyst screenings (Single hits were omitted for clarification).
Table 4. Every catalyst previously used in the GBB-3CR arranged by occurence. 




[20, 26-30, 39, 41, 47-48, 58, 
61-62, 67, 77, 86, 125, 137-138, 




Perchloric acid (HClO4) 15 
[8, 44, 66, 75, 78, 89, 96, 102-
103, 119, 123, 150, 167, 179-
180] 




[34, 40, 55-56, 74, 85, 88, 97, 
107, 130, 141, 164, 181-182] 
Cellulose@Fe2O3 1 [183] 
Acetic acid (AcOH) 13 
[6, 45, 68, 110, 128-129, 142, 
154, 184-188] 




[43, 49, 54, 95, 144, 147, 156, 
158, 166, 189-190] 
(MWCNTs) 1 [100] 




TMSCl 7 [37-38, 53, 152, 155, 169, 176] ZnO NPs 1 [116] 
Montmorillonite K-10 
clay 
6 [19, 64-65, 70, 121, 192] Methanesulfonic acid 1 [52] 
Magnesium chloride 
(MgCl2) 
5 [134, 136, 193-194] Zeolite HY 1 [195] 
Ytterbium triflate 
(Yb(OTf)3) 
4 [105, 131-132, 153] SnCl2.2H2O 1 [127] 








Indium triflate (In(OTf)3) 3 [108-109, 122] γ-Fe2O3@SiO2-OSO3H 1 [71] 
Trifluoro acetic acid 
(TFA) 
2 [82, 165] 
cationic polyurethane 
dispersions (CPUDs) 
1 [76]  
Bismuth chloride (BiCl3) 2 [81, 91] p-TsCl 1 [77] 
Silica sulfuric acid 2 [126, 148] Iodine 1 [135] 
Lanthanum chloride 
(LaCl3.7H2O) 
2 [92, 104] (TBBDA) 1 [83] 
Piperidine 2 [162-163] (PBBS) 1 [83] 
Silver triflate (AgOTf) 1 [113] nano-LaMnO3 1 [90] 
Ionic liquid [bmim]Br 1 [124] NH2‐MIL‐53(Al) 1 [111] 
Ionic liquid [bmim]BF4 1 [70] CuI L-Proline 1 [33] 
Aluminum chloride 
(AlCl3) 
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Table 4 summarizes the catalysts applied in the GBB-
3CR, which give the highest yield in the described 
model reaction. Surprisingly not every catalyst 
screening includes the often excellent performing 
catalysts (Sc(OTf)3, HClO4, and p-TSA). Nearly 50 
different catalysts were described as high yielding, 
indicating a great scope and freedom for selecting the 
catalyst of choice. There are some reports of catalyst 
free GBB-3CR’s, that run perfectly fine without any 
additional reagent. An uncatalyzed GBB-3CR was first 
reported by Lyon et. al. employing immobilized 
glyoxylic acid on macroporous polystyrene carbonate 
(MP-glyoxylate) as a formaldehyde equivalent. The 
decarboxylation leaves a 2-unsubstituted 3-amino-
imidazo[1,2-a] heterocycle without use of any catalysts 
in a yield of 71% (Scheme 16).[42] Further reports of 
catalyst free GBB-3CR’s employ bifunctional building 
blocks that hold a carboxylic acid which probably 
catalyzes the reaction. Truly catalyst free reactions are 
only recently reported by Sharma et al., but seem to 
work exclusively in a reaction using 2-aminothiazole 
under microwave conditions.[160-161, 171-172, 196] In some of 
the catalyst-free reactions, a carboxylic acid functional 
group was found in one of the three components that 
facilitated the reaction in good yields, although it must 
be noted, that the use of carboxylic acids will show 
Passerini poisoning. This side reaction is driven by the 
presence of 3 components; aldehyde, isocyanide and 
carboxylic acid that allow for the P-3CR to happen 
(Scheme 19). 
 
Scheme 19. The P-3CR is competing with the GBB-3CR when carboxylic acids are used as catalyst, consuming the aldehyde and isocyanide 
components that otherwise would be consumed by the GBB-3CR. 
As most Lewis acids rapidly decompose or get 
deactivated when they come in contact with water, 
anhydrous conditions are usually required when 
running a Lewis acid catalyzed GBB-3CR. Sc(OTf)3 is, 
however, more stable and even applied in aqueous 
media as an Lewis acid.[197] The GBB-3CR is a 
condensation reaction, the formation of a water 
molecule would explain why scandium triflate is such a 
successful catalyst in this reaction. The only 
disadvantage noteworthy is that scandium triflate has 
the ability to polymerize isocyanides, explaining the 
darkening of some reaction mixtures when this catalyst 
is applied.[141] Phenylisocyanides are prone to 
polymerization and amongst them unsubstituted 
phenylisocyanide most.[198-200] 
Base catalyzed GBB-3CR 
Sun et al. reported in 2013 the first application of 
piperidine (35) as a Brønsted base catalyst for the 
GBB-3CR, which was applied to overcome the need to 
run a deprotection-cyclization-alkylation sequence to 
obtain their tetracyclic compound. Later in 2013, Sun et 
al. reported the same strategy without the post 
modifications and therefore these base catalyzed 
conditions could be applied for the standard GBB-
3CR.[162-163] In the plausible mechanism, piperidine is 
initially involved in the formation of the Schiff base, 
then with the introduction of the isocyanide component, 
the [4+1] cycloaddition takes place, where piperidine 
facilitates the 1,3-H shift resulting in rearomatization, 
giving the GBB-3CR product as depicted in scheme 20. 
 







Scheme 20. Plausible mechanism for the piperidine catalyzed GBB-3CR projected on methyl 9-butyl-3-(tert-butylamino)-2-phenyl-9H-
benzo[d]imidazo[1,2-a]imidazole-6-carboxylate (36) and its corresponding X-ray structure. 
Sun et al. reports the first Brønsted base catalyzed 
GBB-3CR of 2-aminobenzimidazoles 37, methyl 2-
formylbenzoate 38 and isocyanides, piperidine was 
herein used as catalyst.[163] In their search for a post 
modification on the MCR product, an intramolecular 
cyclization of the secondary amine with the methyl 
ester was performed. The secondary amine was arising 
from the isocyanide input as mostly cleavable 
isocyanides were utilized. They envisioned a tandem 
GBB-3CR and post modification sequence in a single 
step resulting in 20 compounds with a yield varying 
between 34 – 95% (scheme 21). The heterocyclic 
benzimidazole and dihydropyrimidine fragments 
combined are promising compounds as these are 
associated with PARP, topoisomerase I, INOS, PI3K 
and PrCP inhibition.  
 
 
Scheme 21. Preparation of polyheterocyclic 39 unambiguously confirmed by X-ray structure analysis (CCDC 850793). 
Solvents used in the GBB-3CR 
Around 30 solvents and solvent mixtures used in the 
GBB-3CR were analyzed and discussed. Looking at 
the occurrence, methanol is by far the most popular 
solvent for the GBB-3CR reaction. This is largely 
attributed to the fact that the highest yields without  
many side products can be achieved with this solvent, 
the ease of removal and the ability to dissolve quite 
some polar catalysts and starting materials as well as 
more apolar reactants. Discussion of the solvents such 
as methanol trapping and methanol mediated 
intermediates rise the question on how broad the 
solvent range is and whether other solvents than 
methanol should be applied in the GBB-3CR. 
Furthermore, the stability of the intermediates from 
pathway A and B (Scheme 4) are predicted to have 
different stabilities that vary with the used solvent and 
therefore would yield either one of the two isomers or 
the trapped side product.[43] While focusing on solvent 
screens and suitable solvents for the GBB-3CR, it is 
remarkable that the 2nd most frequent applied reaction 
conditions is actually solvent-less. The solvent-less 
reports show that neat reactions with simple stirring or 
mechanical mixing such as ball-milling will yield the 
GBB-3CR compounds as well, but often require more 
exotic catalysts such as zeolite HY, Montmorillonite K-
10 clay and nano-magnetically modified sulfuric acid.[19, 
71, 195] The use of water in a catalyst free GBB-3CR is 
not only working, but also affords GBB-3CR products in 
high yields. The aforementioned mechanism should be 
different from the reaction usually following the 
concerted [4+1] cycloaddition through iminium ions but 
rather a non-concerted 5-exo-dig pathway. The 
protonation of the imine is in general performed with 
Brønsted acids, in the case of water without catalysts 
this is unlikely to happen since the pKa of water is 
higher than pKa’s found for iminium ions.[171] 






Additionally the Woodward-Hoffmann rules which 
indicates that the uncatalyzed concerted [4+1] 
cycloaddition is in fact symmetry-forbidden. The GBB-
3CR is, however, mostly performed with a catalyst, 
which disrupts the symmetry and therefore allowing the 
[4+1] cycloaddition.[201] Considering the possibility of 
using water or a percentage of water in EtOH; it might 
be odd that several reports, indicate that anhydrous 
conditions (dry methanol, dry MeCN and so on) are 
required for the GBB-3CR while the individual starting 
materials and catalysts aren’t sensitive to water, with 
the exception of some Lewis acids catalysts. Water, 
however, has the downside to negatively affect the 
speed of the reaction, anhydrous solvents and the use 
of a dehydrating agent could greatly increase the 
reaction rate.[34] The use of non-protic apolar solvents 
would suppress the intermediate in pathway B, yielding 
exclusively the product of pathway A; imidazo[1,2-
a]pyrimidines. Toluene is such a solvent and is found 
quite often to be used together with ammonium 
chloride as catalyst with heating between 80 °C toward 
reflux temperatures, ruling out formation of any 
regioisomers getting exclusively the pathway A product 
(Scheme 4). Interestingly, while attempts were made to 
find conditions to control the regioselectivity towards 
pathway B, Stephenson et al. reported an alternative 
route, applying a base assisted Dimroth rearrangement 
giving access to the inverse GBB-3CR regioisomer with 
full conversion as depicted in scheme 22.[47] The 
stability of the regioisomer is the driving force behind 




Scheme 22. The Dimroth rearrangement gives access to both regioisomers. A: The rearrangement is performed under basic conditions while 
heating. B: The proposed mechanism, driven by the stability of the product and properties of the initial starting material, such as aromaticity of the 
ring, bulkiness of substituents and solvent. 
Solvents such as DMSO, DMF and PEG-400 are in 
general not the solvents of choice because of their high 
boiling points and difficulties to remove during workup. 
They prove, however, to be quite useful when solubility 
issues with highly polar starting materials are present 
such as the aforementioned amidine containing 
nucleobases.[36, 146]  
 
Table 5. All the solvents used in the GBB-3CR. 
 
Solvent References Occurence Solvent References Occurence 
MeOH 
[6, 8, 26-28, 30, 39, 45, 51, 54-56, 
61, 66, 68, 74-75, 78, 87, 96-100, 
103, 108, 110, 118, 120, 123, 125-
126, 128, 130, 136, 141-142, 150, 
153-154, 156, 166-168, 177, 181, 
51 1:1 EtOH:H2O [165, 180] 2 








[19, 60, 71, 79, 81, 83, 85, 90, 92-93, 
101, 105, 111-112, 127, 133, 140, 
147-148, 161, 172, 192, 195] 
23 Water [46, 76] 2 
Toluene 
[43, 49, 52, 70, 95, 109, 144-145, 
158-159, 163-164, 171, 186, 189-
190] 
17 DMSO [33, 36] 2 
EtOH 
[57, 84, 89, 104, 113, 115-116, 121-
122, 131-132, 134-135, 139, 160, 
193] 
16 DMF [146, 180] 2 
MeCN 
[53, 69, 72-73, 77, 117, 152, 155, 
169, 176, 182] 
9 MeOH:DCE [42] 1 
2:3 MeOH:CH2Cl2 [58, 62, 80, 137-138] 5 TFE:DCE 1:1 [67] 1 
n-BuOH [59, 94, 119, 194] 4 DCE [162] 1 
3:1 MeOH:CH2Cl2 [20, 39, 41] 3 1:1 MeOH:CH2Cl2 [129] 1 
1:3 MeOH:CH2Cl2 [31, 86, 143] 3 1:4 MeOH:CH2Cl2 [47] 1 
Ionic liquid [bmim]Br; 
DES 
[106, 114, 124] 3 1:2 MeOH:CH2Cl2 [48] 1 
1,4-Dioxane [50, 64-65] 3 1:1 EtOH:CH2Cl2 [107] 1 
MEOH/MeCN [37-38, 203] 3 2:3 Ethanol:H2O [170] 1 




TFE [32, 180] 2 DMSO:H2O 1:1 [29] 1 
CH2Cl2 [34, 102] 2 Et2O [88] 1 
 
Biologically active compounds  
Quite often the imidazo[1,2-a]-heterocycles that arise 
from the GBB-3CR are linked to known drugs such as 
Minodronic acid (40), Saripidem (41) Zolpidem (42) and 
other members of the so-called Z-drug group of 
tranquilizers. There are however no reports that GBB-
3CR compounds act in a similar way as Z-drugs on the 
GABAA receptor. The difference between Z-drugs and 
GBB-3CR compounds is found in the exocyclic 
secondary amine, originating from the isocyanide 
component. This amine enables ionic or hydrogen 
bonding, thus having its own influence on the binding 
affinity with various protein targets. As a whole it might 
be better to address real examples of the GBB-3CR 
scaffold and their associated biological activity. 
Examples of 3-aminoimidazo[1,2a]pyridines are shown 
in multiple pharmaceutical drugs or candidates 43-45 
(Scheme 23).[205] Most notably, the late stage autotaxin 
inhibitor GLPG-1690 (45) for the treatment of idiopathic 
pulmonary fibrosis (IPF) which has been discovered 
and developed whereby the GBB-3CR chemistry 
played a key role.[186, 194]  
 







Scheme 23. Examples of imidazo[1,2a]pyridines 40-42 and 3-aminoimidazo[1,2a]pyridines, containing the GBB-3CR scaffolds (blue) reported as 
bioactive leads; 43 anti-inflammatory 44 anticancer, 45 anti-fibrosis. 
 
Only in 2009 the first biological target was addressed 
and published by using a true GBB scaffold as reported 
by Fraga et al.[184] In their efforts to combine the 
structural features of (46), a selective p38 MAPK 
inhibitor, (47) celecoxib a PGHS-2 inhibitor and (48) 
also a p38 MAPK inhibitor a GBB-3CR scaffold was 
used. The main target was to obtain 
polypharmacological 3-arylamine-imidazo[1,2-
a]pyridine derivatives with anti-inflammatory and 
analgesic MOA (Scheme 24). 
 
 
Scheme 24. Synthesis of substituted imidazo[1,2-a]pyridine derivatives as anti-inflammatory and analgesic drugs. 
This approach resulted in compound 49 which was 
identified as PGHS-2 inhibitor (IC50 = 18.5 µM) and acts 
similar to the p38 MAPK inhibitor SB-203580, reverting 
capsaicin-induced thermal hyperalgesia, a pain model 
to assess analgesic properties. Compound 50 is a 
novel PGHS-2 inhibitor, with an ED50 = 22.7 µmol·kg
-1, 
10-fold more potent than celecoxib. 
During a study on the TB targets M. tuberculosis 
glutamine synthetase (MtGS) inhibitory effect, a hit to 
lead exercise was performed on 3-amino-imidazo[1,2-
a]pyridines as these were identified as MtGS inhibitors 
after a high-throughput screening.[193] Two libraries 
were synthesized the first via a microwave assisted 
GBB-3CR sequence for 20-30 min at 160 °C and the 
second via a post-modification on the pyridine 6-
position halogen under Suzuki coupling conditions to 
study the effect of hydrophobic groups such as aryl 
moieties 52 (Scheme 25). Unfortunately, the Suzuki 
coupling did not lead to an improvement in IC50 value, 
leaving the aryl halides 51 themselves as potent 






inhibitors for this target. In a subsequent paper , lead 
optimization did result in a series of potent compounds, 
53 was showing a five-fold improvement with an IC50 = 
1,6µM.[134] The mode of binding of 53 was discussed 
according to its co-crystalstructure with MtGS in the 
structural biology section. 
Scheme 25. Synthesis and optimizing of MtGS inhibitors. 
 
Three years after their patent application, Djuric et al. 
published the work of 5-substituted indazoles as kinase 
inhibitors such as Gsk3β, Rock2, and Egfr,[61] by using 
MCR methodologies such as the GBB-3CR with 
pyrimidines for imidazopyrimidines, thioamides for 
thiazolyl-indazoles and van Leusen TosMICs for 
imidazole substituents.  
 
Scheme 26. 5-substituted indazoles as kinase inhibitors.  
Introduction of the indazole was achieved through the 
use of indazole-5-carbaldehyde as reactant in different 
multicomponent reactions and afforded compounds as 
54-56. The imidazole[1,2-a]pyrimidine 54, GBB-3CR 
product, showed the highest inhibition against Gsk3β, 
imidazopyridine 55 was however, much less potent. 
Choosing different substituents on the amino group, 
coming from the isocyanide input (56), selective 
inhibition for Rock2 could be fine-tuned as well. 
Al-Tel et al described the synthesis of a series of 
imidazo[1,2-a]pyridine and imidazo[2,1-
b][1,3]benzothiazole carrying quinolone and indole 
moieties introduced via the aldehyde component. Many 
of the synthesized compounds showed both 
antibacterial and antifungal activities. A very potent 
broad-spectrum antibiotic was identified as compound 
57 depicted in scheme 27.[138] 
 
 
Scheme 27. Various GBB-3CR bioactive compounds. 
The effect of imidazo[1,2-a]pyridines was studied on 
colon cancer cell lines by Koning et al. by showing 
apoptosis inducing effects in HT-29 and Caco-2 cancer 
cells.[65] Compounds 58 and 59 showed a cytotoxic 
effect towards the Huh7 cell line at low µM 






concentrations and interestingly minimal cytotoxicity 
against white blood cells. 
Schneider et al. performed a chemical advanced 
template search (CATS) for target profiling. CATS use 
topological descriptors generated from known binders 
and to these descriptors it assigns features such as 
lipophilic, aromatic, hydrogen-bond donors and 
hydrogen-bond acceptors to find new chemotypes. This 
virtual target screening yielded a library in which the 
starting point was the GBB-3CR. From the results, 
3840 virtual products, the top 9 compounds were 
synthesized for PI3Ka inhibition.[78] Four out of nine 
exhibited activity, with the most active compound 60 
showing an IC50 = 131 µM confirming CATS usefulness 
as a tool to predict targets of virtually generated 
compounds. In addition, a set of 57 predicted 
compounds, with highest joint prediction scores for 
PI3K and DNA topoisomerases, were synthesized 
using a microwave assisted approach with perchloric 
acid as catalyst. Although no human DNA 
topoisomerase II inhibition was observed, four new 
compounds showed inhibitory effects on bacterial DNA 
gyrase such a compound 61, a bacterial type II 
topoisomerase.  
In silico screening was initiated by Brenk et al. to 
produce a library of novel kinase inhibitors derived from 
commercially available fragments.[151] As a core 
structure they’ve chosen a ring system with heteroatom 
containing functional groups. After applying several 
selection steps, the number of hits was brought down 
from over two million compounds to 265 that yielded in 
186 compounds being successfully synthesized. 17 of 
those were prepared using the GBB-3CR, starting from 
3-amino-1,2,4-triazole, aldehydes and isocyanides, 
catalyzed with HClO4 in MeOH at room temperature. 
One of the obtained compounds 62 showed activity 
against the kinases EPH-B3 (158µM) and FGF-R1 (469 
µM). 
Similar imidazo[2,1-c][1,2,4]triazoles derivatives 
were reported to possess antimicrobial and antioxidant 
activities by El Kaim et al. [168] The reaction conditions 
were different as compared to the method described by 
Akbarzadeh.[158] A Sc(OTf)3 catalyzed reaction with 
substituted benzaldehydes, various isocyanides and 
substituted 5-amino-1,2,4-triazoles was performed in 
DMF (80 °C, 30h) to produce a small collection of 
compounds with yields between 54 and 72%, the best 
performing compound 63 possesses both antifungal 
and microbial activity.  
Another report from 2011 by Al-Tel et al. describes 
the identification of imidazopyridines derivatized with 
benzimidazole and/or arylimidazole as potent β-
secretase inhibitors.[62] In multiple rounds the GBB-3CR 
compound 64 gave a sub micro molar activity, post 
modification by removal of the t-butylamine group, a 
40-fold increase in activity was achieved. The best 
compound 65 showed nanomolar potency for the 
BACE1 enzyme associated with Alzheimer´s disease.  
 
Scheme 28. Highly selective β-Secretase inhibitors of the BACE1 
enzyme. 
Baviskar et al. published in 2011 their work on novel 
topoisomerase IIα inhibitors as anticancer agents. With 
the aid of molecular docking studies they predicted 
bicyclic N-fused aminoimidazoles as potential human 
topoisomerase IIα (hTopoIIα).[63, 94] Based on the 
previous reported topo II inhibitors in combination with 
known drugs containing an imidazo[1,2-a] scaffold, a 
library was synthesized using the GBB-3CR. The result 
is a GBB-3CR scaffolds, by heating the corresponding 
heterocyclic amidine, aldehyde and isocyanide with a 
catalytic amount of ZrCl4 at 50 °C in PEG-400 or under 
MW conditions at 140 °C in n-butanol. In some 
examples the t-butyl group was cleaved using HBF4 
yielding primary amines exhibiting similar activities, 
multiple compounds 65-70 shown higher potency 
anticancer activity as compared to 5-fluorouracil and 
etoposide in kidney cancer cells. Introduction of C2-
biaryl and C6-aryl substitutions on the same 
imidazo[1,2-a]-pyridine/pyrazine scaffold resulted in 
compound 69 which showed inhibitory effects in the 
catalytic cycle of hTopoIIα, additional studies suggests 
that its binds similar as compared to merbarone (a 
known catalytic inhibitor of hTopoIIα) overlapping the 
etoposide binding domain. 
 
 







Scheme 29. Synthesis, screening and optimizing of hTopoIIα inhibitor
Callejo et al. reported a new cancer therapeutic 
approach by inhibition of the kinase B-Raf.[149] In a 
virtual screening they identified imidazo[1,2-a]pyrazines 
as a binder of B-Raf, in a subsequent synthesis of a 
small library they found the derivative with an indanone 
oxime substituent 71 to be highly potent with an IC50 of 
4 nM. Exchange of the furfural moiety lead to 
compounds 72 and 73 showing improvement on B-Raf 
with an inhibition <2 and 0,2 nM respectively. 
 
Scheme 30. Imidazo[1,2-a]pyrazine based B-Raf inhibitors and its 
SAR assisted evolution towards sub-nanomolar inhibitors. 
Further SAR optimizing led to replacement of the 
imidazo[1,2-a]pyrazine moiety by thienopyridines 72 
with improved inbibition (<2nM) and ultimately with 
furopyridines 73 bearing superior sub-nanomolar 
activity (scheme 30). 
Chatterjee et al. described a screening campaign 
using the public malaria database for the discovery of 
novel chemotypes that could inhibit Plasmodium 
falciparum, a selection was made of compounds that 
matched criteria such as good potency (IC50 of <1µM), 
good safety index, (>20-fold in a six-cell line toxicity 
panel) and easy synthesis. The imidazolopiperazine 
moiety was found to be an attractive hit, based on the 
aforementioned criteria.[150]  
 
Scheme 31. Post modifications of GBB-3CR product 74 lead to 
potent anti-malarial compound 75 
The imidazolopiperazines 74 were accessed by 
performing a GBB-3CR in MeOH at RT catalyzed with 
HClO4, followed by reduction with PtO2 under hydrogen 
atmosphere. The most potent compound 75 exhibited 
an IC50 of 4 and 3 nM on the P. falciparum strains W2 
and 3D7 respectively.  
David et al. reported the use of pyridines, isocyanides 
and benzaldehydes in a microwave assisted GBB-3CR. 
Some analogues  of the imidazo[1,2-a]pyridine 
products were found to exhibit activation of the TLR8-
dependent NF-κB signaling. As the GBB-3CR was 
discovered by using pyrimidines as a variation of the 
amine component in the U-4CR, a similar phenomenon 
that was observed when performing a GBB-3CR with 
pyridoxal 76 as aldehyde component. Surprisingly the 
use of pyridoxal 76 as benzaldehyde component did 
not yield imidazo[1,2-a]pyrazines/pyridine 77, but the 
unexpected furo[2,3c]pyridine scaffold 78. Beyond the 
scope of this paper, they proposed a mechanism and 
explored scope and limitation of this reaction. The 
reaction follows the typical GBB-3CR mechanism of the 
imine formation and attack of the isocyanide, but the 
otherwise [4+1] cycloaddition concerning the 
nucleophilic attack of the endocyclic amine with the 
carbene of the isocyanide does not take place. The 
proposed mechanism rather proceeds in attack of the 
phenolic hydroxyl directed by steric hindrance of the 
apposing benzylic hydroxyl group.  The use of anilines 
together with pyridoxal resulted in formation of the 
furo[2,3c]pyridine as well. Replacement of pyridoxal 
with the very similar salicyl aldehyde did however yield 
the usual GBB-3CR scaffold 79, likely due to the 
absence of the bulky hydroxymethylene group in this 
otherwise similar aldehyde. The obtained imidazo[1,2-
a]pyridin-3-amines were TLR7/8 inactive, but showed 
bacteriostatic activity against Gram-positive bacteria. 
SAR studies led to the synthesis of a library of 24 
compounds with the emphasis on the size of aryl 
aldehydes, difference between 2-aminopyridines vs 2-
aminopyrazines and aliphatic or aromatic 
isocyanides.[73] The aim was to assess whether 
modifications were possible without loss of antibacterial 
activity, resulting in 80 as best compound. 
 







Scheme 32. Discovery of side reactions accompanied with use of pyridoxal as aldehyde component, compound 79 (CCDC-893566) confirmed by 
X-ray structure analysis. 
Anabasine 81 a natural product was used by 
Krasavin et al. as a template to prepare hydrazo-Ugi 
and GBB-3CR derivatives were evaluated as agonists 
and antagonists of nAChR. Targeting this family of 
neurotransmission receptors could lead to drugs for the 
treatment of associated with PD, AD, schizophrenia 
and depression.[176]  
 
 
Scheme 33. Anabasine derived GBB-3CR products as binders of nAChR. 
The five GBB-3CR products were synthesized in low to 
moderate yields 20-53%, employing various 
isocyanides, modified anabasine 2-aminopyridine and 
substituted benzaldehydes in MeCN, 70 °C using an 
stoichiometric amount of TMSCl as Lewis acid 
promoter (Scheme 33).  
 
The use of a alkynylbenzaldehydes 83 in the GBB-3CR 
allows for post modifications such as metal catalyzed 
intramolecular cyclization yielding a library of 
compounds, some with strong cytotoxicity against the 
HeLa cell line, due to binding affinity with the G-
quadruplex DNA motif, thus exhibiting anti-proliferative 
activity as described by Shen et al.[206] The cyclization 
to the tricyclic compounds, such as 84, was performed 
in a domino one pot approach of the Yb(OTf)3 
catalyzed GBB-3CR between 2-aminopyridines, 
isocyanides and 2-alkynylbenzaldehyde followed by a 




Scheme 34. In total a library of 23 compounds was synthesized, in which 84 showed the best HeLa cell potency (IC50 = 0,58 µM). 






Proschak et al. reports hybrid imidazo[1,2-a]pyridine 
and an urea moiety as dual soluble epoxide hydrolase 
(sHE)/ 5-lipoxygenase (5-LOX) inhibitors.[128] A three or 
four step approach was used to introduce both the urea 
and imidazo[1,2-a]pyridine elements. In total a library of 
22 compounds were synthesized in an AcOH catalyzed 
GBB-3CR approach in MeOH in yields varying between 
7-64% and showing good inhibition potential on 
recombinant enzyme on both targets. The best 5-LOX 
inhibitor 85 was not the best sHE inhibitor (86), and it is 
to be evaluated whether equipotent inhibition is favored 
over higher inhibition of one of the two targets. 
 
 
Scheme 35. Combined urea and GBB-3CR products synthesized in an 8-step sequence. 
In 2011 Al-Tell et al. described the application of 
various subsequent MCR’s.[58] The carboxylic acid 
group attached to one of the three typical GBB-3CR 
starting materials would not participate in this MCR 
reaction, but is useful for follow up MCR chemistry via 
for example the U-4CR to synthesize antibiotics.[80] The 
six components introduced in two sequential reactions, 
yielded 40 polyfunctionalized imidazopyridine, 
pyrimidine and pyrazine derivatives and were screened 
against multiple bacterial strains such as 
Staphylococcus aureus, Escherichia coli, 
Pseudomonas aeruginosa and screened against two 
human cancer cell lines; breast carcinoma (MCF7), 
A549 (lung cancer cell line) and melanoma (M8).  
 








Scheme 36. Application of a subsequent MCR approach to conveniently obtain complex compounds, exhibiting both antibacterial and anticancer 
properties. 
Five of the synthesized compounds 87-91 were found 
to exhibit lower IC50
 values compared with the internal 
standard doxorubicin, against A549, M8 and MCF7 cell 
lines. Moreover, compound 92 exhibits a high potency 
against breast cancer. 
Vendrell et al. reported the synthesis of 
functionalized BODIPY probes to introduce 
fluorescence in otherwise difficult accessible 
structures.[82] While BODIPY dyes were previously 
derivatized via BODIPY containing an amine or 
carboxylic acid substituent respectively, this paper 
focuses on the preparation of isocyanide functionalized 
BODIPY (93).[207-211] The application of this dye was 
found through isocyanide-based MCR chemistry for the 
aid of in vivo imaging of phagocytic macrophages. 
Different IMCR compounds were synthetized as the 
GBB-3R variant 94, and incubated with A549 cells and 
although all the adducts readily entered cells at 
concentrations in the nanomolar range, the Ugi adduct 
95 exhibited the best coloured images (scheme 37).  
 
  
Scheme 37. BODIPY isocyanide 93 used as fluorescent tag. Compound 95 exhibit fluorescence in A549 cells as depicted in image 7 on the right. 
Reprinted (adapted) with permission from reference [82] Copyright 2013 American Chemical Society.  
Glyoxylic acid based GBB was employed by Li el al. to 
obtain a series of mono-substituted imidazopyridines 
that target the RET kinase class, a known 
oncogene.[212] In their first series, 100 MCR fragments 






were synthesized by a acetic acid catalyzed GBB-3CR 
using substituted 2 aminopyridines, isocyanides and 
glyoxylic acid. Screening resulted in a hit 96 which was 
subjected to computational binding analysis in the RET 
kinase. The phenyl moiety accesses a lyophilic pocket 
that could be extended from the allosteric pocket. 
Another non-MCR series of compounds were 
synthesized to engage this adjacent lipophilic pocket, 
resulting in an increase of inhibitory potency as shown 
by two compounds (97 = 0.21 µM and 98 = 0.75 µM) 
thus identified as novel RET kinase inhibitors (Scheme 
38). 
 
Scheme 38. Initial GBB-3CR hit design towards novel non-MCR 
RET inhibitors. 
Imidazo[1,2-a]pyridine-N-glycinylhydrazone derivatives 
were applied as inhibitors of tumor necrosis factor 
alpha (TNF-α) by Fraga et al.[84] The design of the 
scaffold was performed by combining two earlier 
described TNF-α inhibitors wherein the N-phenyl-
pyrazole nucleus 99 was replaced with the heterocyclic 
imidazo[1,2-a]pyridine isostere, easily accessible by 




Scheme 39. Imidazo[1,2-a]pyridine-N-glycinylhydrazone 
derivatives as TNF-α inhibitors. 
Via an acetic acid catalyzed reaction of benzaldehyde 
or pivaldehyde, 2-aminopyridine and ethyl 2-
isocyanoacetate two GBB-3CR products were obtained 
with yields of 65 and 75% respectively. Post 
modification with hydrazine and subsequent hydrazone 
formation yielded 11 products that were screened in a 
TNF-α production assay, ultimately leading to the most 
active 100, equipotent with SB-203580 (101) a known 
p38 MAPK inhibitor herein applied as anti TNF-α agent.  
Inhibition of the BET bromodomain is a promising 
approach as anti-cancer therapy. In a fragment based 
optimizing strategy, Bradner et al. used the 
dimethylisoxazole biasing element as a key fragment 
and screened on BRD4 and BRD4-dependent lines, 
using different heterocyclic substituents to gather 
information on preferred regiochemistry.[86] Bromo  
substituted benzaldehydes were employed in the µW 
assisted, Sc(OTf3) catalyzed GBB-3CR to perform a 
follow-up Suzuki coupling in order to introduce the 3,5-
dimethylisoxazole warhead. The best compound is built 
around the para-substituted phenyl-imidazo[1,2-
a]pyrazine scaffold and a small library of 29 
compounds was synthesized for SAR optimizing, 
resulting in lead compound 102.  
 
   
Scheme 40. GBB-3CR compound 102 as potent BET 
bromodomain inhibitor.  
In continuation of Shen et al.[206] another HeLa 
cytotoxic series of 6H-pyrido[2’,1’:2,3]imidazo[4,5-
c]isoquinolin-5(6H)-ones was reported by the same 
research group[87] In this report the tetracyclic profile 
was maintained, however the alkynyl moiety was 
replaced with a carboxylic acid (phthaldehydic acid) 
which direct reacts with the secondary amine, formed 
in the GBB-3CR (scheme 41). 
 
 






Scheme 41. Application of the bi-functional phthaldehydic acid 103 giving access to tetracyclic heterocycles with example 104 exhibiting HeLa 
toxicity (IC50 = 1.8 µM). 
Shen et al. published, more work on cytotoxic 
compounds while abandoning the tetracyclic scaffold, 
switching to a bicyclic scaffold exhibiting intramolecular 
hydrogen bonding to form pseudo-tetracycles.[177] A 
more straightforward methodology, as it only comprises 
a single GBB-3CR step. The library was step by step 
optimized with variations of all three components. The 
hydrogen bonding ability was most successful when an 
ortho substituted hydroxyl- or methoxybenzaldehyde 
component was used. A 100-fold activity increase over 
compound 104 was realized with compound 105.  
Foroumadi et al. reported novel anticancer agents 
based on N-fused aminoimidazole derivatives with 
triazine analogs.[158] The basis of this compound were a 
combination of potent topoisomerase IIα inhibitors[63] 
and triazines[213] to yield the N-cyclohexyl-3,4-
diphenylimidazo[2,1-c][1,2,4]triazin-6-amine scaffold 
109 (scheme 42). The aminotriazine 108 was prepared 
from condensation of benzil 106 with aminoguanidine 
107. Noteworthy are the conditions that were found 
whilst optimizing the GBB model reaction. The reaction 
with toluene under reflux conditions gave the highest 
yield of 70% in the presence of 1 equivalent ammonium 
chloride as compared to 45% without. 
 
Scheme 42. A series of anticancer agents, through the clever condensation of benzyl 106 and aminoguanidine 107 and subsequent GBB-3CR. 
 
A small library of 20 compounds was prepared and 
their cytotoxicity was assessed on HL60, MCF-7 and 
MOL-4 by the MTT reduction assay against cisplatin 
and doxorubicin. The highest potency of compounds 
110 and 111 was observed on MCF-7 and HL60 cells 
respectively. SAR optimizing showed that replacing the 
7-aryl moiety with pyridyl or furan-2-yl (compounds 112 
and 113) gave improvement of the potency against 
MOLT-4.  
In a substrate activity screening, Veken et al. 
decorated an imidazo-[1,2-a]pyridine scaffold with a 
library of fragments that bind to the urokinase 
plasminogen activator (uPA) S1 pocket.[96] This target 
is a biomarker and therapeutic target for cancer types 
such as breast, ovarian and pancreatic cancer. In two 
rounds the imidazopyridine scaffold was optimized. The 
first round focused on mono-substitution with fragments 
on the 3 position of the imidazopyridine scaffold using a 
GBB-3CR to identify fragments that bind to the S1 
pocket. In a second round structural optimization was 
performed by introducing substituents through the 
aminopyridine and aldehyde component. This resulted 
from an IC50 (uPA) value (114) of 9.04 µM towards 
0.097 µM (115) improvement between the first and 
second round respectively (Scheme 43). 
 
 
Scheme 43. Binders of the urokinase Plasminogen Activator (uPA) S1 pocket, round 1 and 2 top performing products. 
The imidazo[1,2-a]pyrazine scaffold is found in 
Heat shock protein 90 (Hsp90) inhibitor PU-H71, using 
the Zolpidem rationale that absence of the amine 
moiety in the 3 position wouldn’t affect the inhibitory 
effects, Shen et al. synthesized a library of substituted 
3,8-diaminoimidazo[1,2-a]pyrazines to target this 
protein.[153] The biggest challenge in these compounds 
was the incorporation of the adenine motif with an 
amine in the 8 position, which will in unprotected form 
participate in the GBB-3CR. Introduction of a chlorine 






at position 8 followed by aminolysis as well as 
protected amines were tried by the authors. The 
resulting lead compound 116 exhibits moderate Hsp90 
inhibition as compared to PU-H71 (117), however, the 
co-crystallization of the reported 3,8-
diaminoimidazo[1,2-a]pyrazines have shown to bind in 
the same way as the known inhibitor (Scheme 44). 
 
 
Scheme 44. Development of novel imidazo[1,2-a]pyrazine based Hsp90 inhibitors. 
Coelenterazione 118 is a bioluminescent 
imidazopyrazine and can be found in several marine 
organisms. The properties such as bioluminescent and 
antioxidant are useful and utilized as optical signaling 
agents for cancer behavior studies. Vuocolo et al. 
reports the synthesis of 3 deoxy- derivatives of 
coelenterazine to improve some of its properties, such 
as its low stability.[154] The 3 deoxy approach brings 




Scheme 45. 3 deoxy- derivatives of coelenterazine as bioluminescent and antioxidant 
 
In this report only t-butylisocyanide was used in a 
acetic acid catalyzed GBB-3CR under dry conditions 
(3Å molecular sieves) yielding compound 119 in 64% 
and in follow up reactions a deprotection and reductive 
deamination (NaNO2/H2SO4) routine was used to 
obtain compound 120. 
Liu et al. describes a library of imidazopyridine and 
quinoxaline derived compounds and introduces 
ferrocene incorporation via the aldehyde or isocyanide 
component through the GBB-3CR, with the aim of 
developing new antioxidants to reduce oxidative 
stress/DNA damage due to reactive oxygen 
species.[104] 
 







Scheme 46. Ferrocene based anti-oxidants. 
The LaCl3.7H2O has proven to be an excellent catalyst 
with yields >84% at a reaction temperature of 60 °C in 
EtOH for 2h. Compounds 121 and 122, the ferrocene 
bearing compounds, were the best in inhibiting DNA 
oxidation. More improvement was made by 
derivatization of the imidazo[1,2-a]quinoxaline 
scaffold.[155] Decoration with ferrocenyl and p-
methoxyphenyl (123) or flavonyl (124) groups on either 
the 2 or 4 position boosted the radical 
suppression/inhibition of DNA oxidation.  
A hybrid structure between imidazo[1,2-a]pyridine 
and coumarins were synthesized by Shah et al. as 
potential Hepatitis C virus replicator inhibitor. [110] The 
20 compounds were synthesized using a AcOH (20 
mol-%) catalyzed GBB-3CR in MeOH at 70 °C for 2h in 
yields between 67-92%. Molecular docking studies 
indicate good binding interactions of compound 125 
with nonstructural protein 5B.  
 
  
Scheme 47. Coumarine based GBB-3CR products, compound 128 was crystalized and the structure was unambiguously verified by X-ray 
analysis (CCDC-1053723). 
Trivedi et al. combined the structural properties of anti-
cancer agents that commonly have a coumarin 
structure and anti-osteoporotic agents holding pyridine 
or imidazole heterocycles into coumarin–imidazo[1,2-
a]pyridine hybrids for the treatment of cancer induced 
osteoporosis.[113] 18 GBB-3CR products were obtained 
using ethanol reflux conditions and 20 mol-% AgOTf 
with excellent yields (71-88%), including compound 
126. Compound 127 was found to possess anti-breast 
cancer activity (MDA-MB-231 IC50 = 14.12 +/- 3.69 µM) 
as well as disrupting the differentiation of osteoblast 
and osteoclast cells and therefore indicating the 
compound as promising hybrid for both aforementioned 
diseases.  
The first-in-class autotaxin (ATX) inhibitor 
GLPG1690 was described by Heckmann et al. and was 
discovered and optimized through the synthesis of a 
2,3,6 trisubstituted imidazo[1,2a]pyridine series, 
identified by HTS.[186, 194] Approximately 100.000 
compounds were subjected to screening in which ATX 
activity is promoting release of the fluorophore FS-3, an 
HTS suitable substitute of LPC, thus easily identifying 






inhibitors by a fluorescence detection assay. The N-
benzyl-2-ethyl-N-methyl-imidazo[1,2-a]pyridin-3-amine 
hit series 128 displayed a IC50 around 30 nM in the FS-
3 assay (Scheme 48).  
 
 
Scheme 48. Autotaxin inhibitors; From hit to lead. 
The metabolic stability of this series was however poor 
and a second series with improved pharmacokinetic 
properties was developed, resulting in an early lead 
compound 129 (IC50 = 122 nM (FS-3 assay). The 
reduced potency gave reason to continue SAR analysis 
and synthesis. Furthermore the ATX activity could not 
be reproduced with biochemical assays; using the 
natural substrate LPC displayed only micromolar 
activity. Extensive optimizing on all substituents, 
assisted by analysis of the binding mode using 
compound 129, resulted in lead compound 130 with a 
potency of 27 nM in the biochemical assay and 22 nM 
in a rat plasma assay. The improved potency was 
achieved through the 6 position by extending the 
substituent and the addition of a basic amine and an H-
bond donor or acceptor. The addition of a nitrile group 
on the thiazole moiety pushes out a high energy water 
by full occupation by the ligand, increasing the potency 
even more. In a second report Heckmann et al. 
describes improvement of lead compound 130, 
focusing on ADMET (hERG and CYP3A4) and PK 
properties (clearance and bioavailability), ultimately 
resulting in the clinical candidate GLPG1690 (131) 
(IC50 = 131 nm). The five-fold loss in activity of 131 was 
outweighed by the absence of CYP3A4 TDI and the 
compound is overall the best combination of activity, 
pharmacokinetic, ADMET and PK properties. The ATX 
inhibitor was further discussed in the structural biology 
section. 
Structural Biology 
Farnesoid X receptors (FXRs) are nuclear hormone 
receptors expressed in high concentration in tissues 
that participate in bilirubin metabolism including the 
kidneys, intestines, and liver. In animal models of 
nonalcoholic fatty liver disease (NAFLD), FXR 
activation protects against fatty liver injury and 
nonalcoholic steatohepatitis (NASH), and improved 
hyperlipidemia, glucose intolerance, and insulin 
sensitivity. Thus, FXR agonists could potentially be 
used as drugs to treat nonalcoholic fatty and 
cholestatic liver diseases. A GBB product 132 was 
described in a cocrystal structure bound to FXR (Figure 
4 A).[214] Remarkably, 132 fits tightly in the pocket 
undergoing a range of hydrogen, pi-stacking and van 
der Waals interactions (Figure 4. C-E).[214] The 2,6-
dimethyl phenyl moiety (derived from the isocyanide) 
ensures an out-of-plane orientation of the two phenyl 
substituents with regard to the imidazopyridine bicycle 
through sterically repulsion which can help to increase 
binding affinity through preorganisation of the binding 
conformation (Figure 4. B).  







Figure 4. GBB product 132 bound to farnesoid X receptor (FXR, PDB ID 5Q12). A) 2D structure of 132; B) scorpion score (14.0) and its heavy 
atom distribution on 132 (color code: red strong to purple weak contribution, grey minor contribution); C) the imidazole-N of 132 acts as a 
hydrogen bond acceptor towards the His451 (2.8 Å); D) 132 forms two pi-stacking interactions between Phe333 and the 2,6-difluorophenyl moiety 
and the Trp458 and the 2-methyl pyridine moiety; E) multiple hydrophobic interactions can be found between all parts of 132 and the surrounding 
hydrophobic receptor amino acids; specifically to mention is FA (red in B) which makes multiple contacts with His298, Met332 and Ala295. 
 
The protein bromodomain (BD) serves the recognition 
of acetylated lysine as in histones and is composed of 
approximately 110 amino acids. In the context of signal 
transduction, the bromodomain function as a "reader" 
of the lysine acetylation. For a family of bromodomains, 
the BET (bromodomain and extra terminal domain) 
family, several compounds are in clinical evaluation. 
Members of the BET family are targets in both human 
cancer and multiple sclerosis. The bromodomain has 
also been investigated as antifungal target. Screening 
a library of ∼80,000 chemically diverse compounds by 
a HTRF inhibition assay revealed GBB 133.[215] 
Compound 133 inhibits the CaBdf1 BD2 with high 
selectivity: HTRF and ITC assays yielded IC50 and Kd 
values of 1.1 and 2.1 μM, respectively, whereas human 
Brd4 BD2 and CaBdf1 BD1 were only weakly inhibited 
(IC50≥40 μM). Moreover, no significant inhibition of any 
human BDs was observed for compound 133 by 
BROMOscan profiling and by an ITC assay on the two 
most sensitive BDs identified by this screen. Only mild 
cytotoxicity was observed towards mammalian cells 
(EC50 ∼60 μM) for compound 133. A cocrystal structure 
of 133 in Candida albicans Bdf1 reveals shape 
complementarity to the receptor and a network of 
hydrogen bonding, pi-stacking, van der Waals 
interactions (Figure 5).  






Figure 5. Second Bromodomain (BD2) from Candida albicans Bdf1 binding to an GBB imidazopyridine (PDB 5N18). A) 2D structure of 133; B) 
scorpion score (5.6) and its heavy atom distribution on 133 (color code: red strong to purple weak contribution, grey minor contribution); ; C) 
overall GBB receptor binding site featuring multiple electrostatic interactions and a string of four signature structural waters (green, yellow and red 
balls) ; D) two water mediated hydrogen bondings including Pro410 carbonyl-H2O-N imidazole and Val460 carbonyl-H2O-p-hydroxyphenyl and 
Asn468 side chain amide-CO and exocyclic NH of isocyanide moiety; E) T-shaped pi-pi interactions between Phe467 and Tyr425 and the phenyl 
groups of the isocyanide and aldehyde components; F) multiple van der Waals interactions involving Phe467, Val415, Ph411, Val474 and Leu420; 
G) a H-bond donor-pi interaction involving the side chain amide NH of Asn468 and the aldehyde phenyl. 
 
Autotaxin (ATX) is a secreted lysophophospholipase D 
that converts lysophosphatidyl choline (LPC) into the 
bioactive phospholipid derivative lysophosphatidic acid 
(LPA). LPA exerts its biological activities through 
activation of the LPA receptors: LPA1−6. The ATX/LPA 
axis is involved in numerous physiological and 
pathophysiological processes. Autotaxin inhibitors have 
been proposed to be useful in various pathologies such 
as cancer, pain, and cholestatic pruritus, as well as 
fibrotic, inflammatory, and cardiovascular diseases.  
Appropriate structural modifications of the initial GBB 
hit lead to 134 with improved ADMET (hERG and 
CYP3A4 TDI) and PK properties (bioavailability and 
clearance).[186] Compound 134 was able to decrease 
LPA levels in mouse plasma. Additionally, compound 
134 demonstrated significant activity in a mouse 
fibrosis model at doses of 10 and 30 mg/kg twice a day, 
with an efficacy comparable or superior to that of the 
reference compound pirfenidone. Compound 134 is 
currently being evaluated in an exploratory phase 2a 
study in idiopathic pulmonary fibrosis patients. 
Compound 134 was also cocrystallized with its target to 
better understand the molecular basis of its disease 
modifying activity (Figure 6). 
 






Figure 6. GBB Imidazo[1,2-a]pyridine derivatives with potent autotaxin/ENPP2 inhibitor activity (PDB ID 5MHP). A) 2D structure of 134; B) 
scorpion score (10.6) and its heavy atom distribution on 134 (color code: red strong to purple weak contribution, grey minor contribution); C) 
overall topology of the interaction of 134 with its receptor featuring multiple hydrophobic, hydrogen bonding and stacking interactions; D) x is 
embedded in a aromatic cage including Phe’s211, 275, 274, Trp261 and His252; Phe274 carbonyl forms a pi-pi interaction with the thiazole sulfur; 
E) two H bond donor pi interactions involve His252 and a structural water molecule; F) a water mediated hydrogen bond involves the azetidine 
carbonyl and the NH of Trp261. 
 
Heat shock protein 90 (HSP-90) is a so-called 
chaperone protein that assists other proteins to fold 
properly, stabilizes proteins against heat stress, and 
aids in protein degradation. It has shown to stabilize 
proteins during cancer development. The natural 
product geldanamycin and derivatives and totally 
synthetic compounds show promising antitumor activity 
in clinical trials and therefore HSP-90 is a validated 
cancer target. The GBB compound 135 was 
synthesized based on the observation of ATP-
competitive Hsp90 inhibitors containing the 8,9-
disubstituted adenine motif, which might be replaced 
with the 2,3-disubstituted 8-aminoimidazo[1,2-
a]pyrazine scaffold (GBB).[153] Additionally, 
computational scaffold hopping exercises suggested 
that a similarly substituted 8-aminoimidazo[1,2-
a]pyrazine might possess Hsp90 inhibitory activity due 
to the remarkable resemblance to PU-H71, an Hsp90 
inhibitor in Phase I clinical trial. The hypothesis proved 
to be trough and multiple GBB compounds with this 
adenosine mimicking patterns showed competitive 
binding to HSP-90. 135 has been cocrystallized with 
HSP-90 (Figure 7) and shows multiple contacts to the 
ATP binding site including hydrogen bonding, pi-
stacking of the piperonyl moiety and van der Waals 
interactions.  
 







Figure 7. GBB compound 135 binding to HSP-90 (PDB ID 4R3M). A) 2D structure of 135; B) scorpion score (14.8) and its heavy atom distribution 
on 135 (color code: red strong to purple weak contribution, grey minor contribution); C) overall receptor ligand interaction involving multiple van der 
Waals, stacking and hydrogen bonding interactions; D) a parallel pi-pi stacking interaction between Phe138 and the moiety 1,2-
methylenedioxybenzene moiety is a strong affinity contributor; E) the adenine-NH2 forms a direct hydrogen bond towards Asp93 carboxylate and a 
tripartite hydrogen bond Leu48 backbone carbonyl and Ser52-OH mediated by two structural water molecules accounting for the adenine-NH2 
importance for binding. 
Glutamine synthetase catalyzes the synthesis of 
glutamine from glutamate and ammonia under 
hydrolysis of adenosine 5’-triphosphate (ATP). The 
enzyme is involved in nitrogen metabolism and cell wall 
biosynthesis in pathogenic mycobacteria and thus 
comprise a potential anti tuberculosis target. ATP-
competitive MtGS inhibitors were identified in a high-
throughput screening (HTS). One hit compound was a 
GBB 3-amino-imidazo[1,2-a]pyridines. This was an 
ideal candidate class for structure–activity relationship 
(SAR) studies, because diverse analogs can easily be 
obtained in one step via GBB-3CR.[134] The best 
compound showed an IC50 of 0.6 M. Co-
crystallization of one of the best inhibitors with MtGS 
136, helped to rationalize the observed SAR (Figure 8). 
 
 






Figure 8. Crystal structure of Mycobacterium tuberculosis glutamine synthetase in complex with GBB 53 (PDB ID 4ACF). A) 2D structure of X; B) 
scorpion score (10.3) and its heavy atom distribution on 53 (color code: red strong to purple weak contribution, grey minor contribution); C) 53 is 
embedded in a hydrophobic site involving Arg364, Phe232, Lys361, Trp282 and Tyr129; D) a halogen bonding between Hi278 backbone carbonyl 
and the Br is identified; E) a parallel pi-pi stacking interaction between Phe231 and the pyridine central part of GBB backbone is formed: F) a ionic 
interaction is spotted between the ligands carboxy group and the Lys361; G) a cation-pi interaction is formed between Arg364 and the pyridine 
part of the GBB backbone; H) the aminobutyl side chain-NH is involved in a direct hydrogen bonding with Lys361 carbonyl and a tripartite water 
mediated network with Trp282 indole NH and Ser280-OH. 
Patents 
The first appearance of the GBB-3CR in patents took 
roughly 3 years when a nitric oxide synthase inhibitor 
was reported by Gruenenthal GmbH.[216] About 100 
patents were filed in the course of 18 years, in which 
some had the imidazo[1,2-a]pyridine/pyrazine as main 
decorated scaffold obtained using the GBB 
methodology, while others reported the scaffold either 
by sequential synthesis and as one of many different 
claimed structures. The GBB-3CR was found in the 
pharmaceutical industry and shortly after its discovery 
patents concerning the [1,2a]imidazo scaffold appeared 
in patent applications, either directly or indirectly as 
seen in the 2004 Patent from Merck & Co. Inc. [217] 
where the double bonds in the originating pyrazine 
were reduced to obtain a piperazine. The drug was with 
various structural modifications brought to the market 
as Sitagliptin, also known under the tradename Januvia. 
As many patents were reported in the last decades, not 
many true GBB-3CR scaffolds were marketed as actual 
drugs. Recently compound KAF156in development by 
Novartis AG, completed phase 2 clinical trials 
(NCT01753323), being effective against the 
Plasmodium falciparum and Plasmodium vivax forms of 
the malaria parasite with clearance of the parasites 
within 2 days.[218-219] More examples of patents that 
leverage the GBB scaffold were listed in table 6. 
 
Table 6. The structures found in the patent were found as GBB products, whereas the listed structures comprise the in general most active 
compound, shown as the active component of interest. 





CNS, Ischemia, Brain 
disease, Shock, 
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The scaffold of the GBB-3CR is one of the 27 MCR 
scaffolds that is included in the AnchorQuery library 
which was recently introduced as powerful tool for 
rational structure-based design of protein-protein 
interaction (PPI) inhibitors.[261] The often deeply buried 
amino acids comprise a major energetic hotspot which 
is leveraged in a pharmacophore model search that 
rapidly screens libraries yielding a possible 31 million 
synthesizable compounds, each containing an anchor 
motif that is bioisosteric to amino acid residues, 
including D, W, Y, F, V and E anchor side chains. 
Important examples of the power of AnchorQuery are 
demonstrated through the role it played in the 
development of novel p53-MDM2 inhibitors and an 
allosteric inhibitor.[262-264] In the virtual screening the 
suggested scaffolds are amenable in one to maximal 
three reaction steps. More specifically, the screening 
platform contains xyz GBB in xyz different 
conformations. Using AnchorQuery as a tool is free of 
charge, accessible via http://anchorquery.csb.pitt.edu 
and will provide all the tools necessary to interactively 
perform online virtual screening, rapidly going through 
millions of compounds with pharmacophore elucidation 
and enrichment analysis queries. A great benefit of the 
screening platform is obviously that a binding 
hypothesis can be immediately tested by 
resynthesizing the virtual hit.  
 
  






Figure 9. Workflow of the online virtual screening platform ANCHOR.QUERY.  
Conclusions 
The GBB-3CR has been described the first-time 20 years ago 
and is currently one of the mostly used MCR reactions. 
According to the definition of the Ugi reaction as an α-addition of 
a Schiff base and a suitable acid component and a 
rearrangement reaction it belongs formally to the same class of 
reactions. Similar to the classical Ugi MCR the GBB-3CR also 
shows a great scope in terms of diversity of starting materials. 
For mostly any combination between aldehydes, isocyanides 
and heterocyclic amidines, with the help of a suitable catalyst, 
the reaction is giving the expected products. Not surprisingly the 
GBB scaffold is described in multiple publications and patents. 
The first derivatives of GBB products have entered clinical trials. 
This is very well in line with the saying that after 15-20 years 
since the discovery of a new reaction first products based on 
new reactions will enter the market. It can be predicted that 
several more bioactive compounds will enter the market in the 
future.  An interesting freely accessible virtual screening platform 
will be useful in the discovery of tool compounds against difficult 
to drug targets. Currently still underdeveloped are materials 
science application of the GBB-3CRs, such as functional 
polymers or organic conductors or light to energy transformers. 
Clearly the GBB scaffold has the potential that many interesting 
electronic and optical applications will be described in the future.  
List of abbreviations 
AcOH  Acetic acid 
AD   Alzheimers disease 
ADMET Absorption, distribution, metabolism, and 
excretion 
ATX   Autotaxin 
3CR   3-component reaction 
BODIPY   Boron-dipyrromethene 
CB2   Cannabinoid receptor type 2 
CH2Cl2  Dichloromethane 
CK2   Casein Kinase II  
DMA   Dimethylaceetamide 
DMF   Dimethylformamide 
DMSO  Dimethylsulfoxide 
ERK   Extracellular signal–regulated kinases 
FDA   Food and Drug Administration 
FGFR3  Fibroblast growth factor receptor 3 
GABA  Gamma aminobutyric acid 
GLP-1  Glucagon-like peptide-1 
h-TRPA1 Transient receptor potential cation channel, 
subfamily A, member 1 
HClO4  Perchloric acid 
HCV   Hepatitis C 
HDAC  Histone deacetylase 
hENPP2 Ectonucleotide 
pyrophosphatase/phosphodiesterase family 
member 2 (ATX) 
HTS   High throughput screening 
IMCR  Isocyanide-based multicomponent reactions 
JNK1  See MAPK8 
LPC   Lysophosphatidylcholine 
MAPK8  Mitogen-activated protein kinase 8  
MCR   Multicomponent reactions 
MDM2  Murine double minute 2 
MeCN  Acetonitrile 
MeOH  Methanol 
MP-CO3  Macroporous polystyrene carbonate  
MTOR  Mammalian target of rapamycin 
MW   Microwave 
NMR   Nuclear magnetic resonance 
P-3CR  Passerini 3-component reaction 
PADAM Passerini-reaction-Amine-Deprotection-Acyl-
Migration  
PD   Parkinsons Disease  
PDGFR  Platelet-derived growth factor receptor 
PEG   Polyethylene glycol 
PET   Positron emmision tomography 
PGHS-2  Prostaglandin-endoperoxide synthase 2 
PI3   Phosphoinositide 3-kinase 
Pim-1  Proto-oncogene serine/threonine-protein kinase 
PK   Pharmacokinetic 
PTSA  para-Toluenesulfonic acid 
p-TSIA  para-Toluenesulfinic acid 
RET   Rearranged during transfection 
SAR   Structure-activity relationship 
Sc(OTf)3  Scandium triflate 
SGLT  Sodium-glucose transport proteins 
SKM   Leukemic cell line  
TDI   Time-dependent inhibition 
Tf   Triflate 
TFE   Trifluoroethanol 
TLC   Thin Layer Chromatography 






TMOF   Trimethyl orthoformate 
TMSN3   Trimethylsilyl azide 
TNFa   Tumor necrosis factor alpha 
TPSO   Translocator protein 
TRIM33   Tripartite motif-containing 33 
U-3CR   Ugi 3-component reaction 
U-4CR   Ugi 4 component reaction 
UDC    Ugi-deprotection-cyclize 
vL-3CR   van Leusen 3 component reaction 
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Over the past twenty years, the Groebke-Blackburn-Bienaymè reaction, one of the youngest iMCRs has gained interest and about 50% of the 
reports were describing the GBB molecules in an application.1 Since 1998 a total of >200 peer reviewed publications and >100 patent 
applications have been reported exploiting the GBB, with a clear trend of increasing interest, particularly in the last decade. The GBB-3CR 
has always attracted (medicinal) chemists due to its versatility and MCR character to lead to interesting 'drug-like' bicyclic compounds. 
Multiple applications were published in material science as well. The GBB-3CR is synthetically demanding as three different building blocks 
have to react with each-other: aldehydes, isocyanides and cyclic 5- or 6-membered amidines. An overview has been made that describes the 
development of the GBB reaction and alongside a tabular analysis was made to show which exact reagents were reported as one of three 
components in the GBB reaction. 
 
 
